viernes, 14 de octubre de 2016

Summary of Notifiable Infectious Diseases and Conditions — United States, 2014 | MMWR

Summary of Notifiable Infectious Diseases and Conditions — United States, 2014 | MMWR

MMWR Weekly
Vol. 63, No. 54
October 14, 2016
PDF of this issue

Summary of Notifiable Infectious Diseases and Conditions — United States, 2014

Deborah A. Adams; Kimberly R. Thomas, MPH; Ruth Ann Jajosky, DMD; Loretta Foster, MPH; Pearl Sharp; Diana H. Onweh; Alan W. Schley; Willie J. Anderson; for the Nationally Notifiable Infectious Conditions Group Division of Health Informatics and Surveillance, Office of Public Health Scientific Services, CDC
View suggested citation


The Summary of Notifiable Infectious Diseases and Conditions—United States, 2014 (hereafter referred to as the summary) contains the official statistics, in tabular and graphic form, for the reported occurrence of nationally notifiable infectious diseases and conditions in the United States for 2014. Unless otherwise noted, data are final totals for 2014 reported as of June 30, 2015. These statistics are collected and compiled from reports sent by U.S. state and territory, New York City, and District of Columbia health departments to the National Notifiable Diseases Surveillance System (NNDSS), which is operated by CDC in collaboration with the Council of State and Territorial Epidemiologists (CSTE). This summary is available at This site also includes summary publications from previous years.
The Highlights section presents noteworthy epidemiologic and prevention information for 2014 for selected infectious diseases and conditions and additional information to aid in the interpretation of surveillance and infectious diseases- and conditions-trend data. Part 1 contains tables showing incident (new) cases and incidence rates for the nationally notifiable infectious diseases and conditions reported during 2014; these tables do not include rows for conditions with zero cases reported in 2014 (Tables 1,2,3,4,5, and 6).* The tables provide the number of cases reported to CDC for 2014 and the distribution of cases by MMWR month, geographic location, and demographic characteristics (e.g., age, sex, race, and ethnicity). Part 1 also includes a table with the reported incidence of notifiable diseases during 2004–2014 and a table enumerating deaths associated with specified notifiable infectious diseases and conditions reported to CDC’s National Center for Health Statistics (NCHS) during 2008–2014 (Tables 7 and 8). Part 2 contains graphs and maps that depict summary data for selected notifiable infectious diseases and conditions described in tabular form in Part 1. Historical notifiable disease data, annotated as Part 3 in previous releases of this summary, will no longer be included in this report. Historical notifiable disease data during 1944–2013 are available online in previous years’ summaries ( The Selected Reading section presents general and disease-specific references for notifiable infectious diseases and conditions. These references provide additional information on surveillance and epidemiologic concerns, diagnostic concerns, and infectious disease-control activities. To increase the usefulness of future editions, comments regarding the current report and descriptions of how information is or could be used are invited. Comments should be e-mailed to with the following subject line: “Annual Summary”.


The infectious diseases and conditions designated by CSTE and CDC as nationally notifiable during 2014 are listed in this section. A notifiable infectious disease or condition is one for which regular, frequent, and timely information regarding individual cases is considered necessary for the prevention and control of the disease or condition. A brief history of the reporting of nationally notifiable infectious diseases and conditions in the United States is available at In 1961, CDC assumed responsibility for the collection of data on nationally notifiable diseases and deaths in 122 U.S. cities. Data are collected through NNDSS, which is neither a single surveillance system nor a method of reporting. Rather, it is a “system of systems”, which is coordinated by CDC at the national level across disease-specific programs to optimize data compilation, analysis, and dissemination of notifiable disease data. Monitoring surveillance data enables public health authorities to detect sudden changes in disease or condition occurrence and distribution, identify changes in agents and host factors, and detect changes in health-care practices. National level surveillance data are compiled from case notification reports of nationally notifiable infectious diseases and conditions submitted from the state, territory, and selected local health departments to CDC.
Cases are first identified through reports of infectious diseases and conditions from the local level to the state or territory. Legislation, regulation, or other rules in those jurisdictions require health-care providers, hospitals, laboratories, and others to provide information on reportable conditions to public health authorities or their agents. Case reporting at the local level protects the public’s health by ensuring the proper identification and follow-up of cases. Public health workers ensure that persons who are already ill receive appropriate treatment; trace contacts who need vaccines, treatment, quarantine, or education; investigate and control outbreaks; eliminate environmental hazards; and close premises where disease transmission is believed to be ongoing.
Although infectious disease and condition reporting is mandated at the state, territory, and local levels by legislation or regulation, state and territory notification to CDC is voluntary. All U.S. state health departments, five territorial health departments, and two local health departments (New York City and District of Columbia) voluntarily notify CDC about nationally notifiable infectious diseases and conditions which are reportable in their jurisdictions; the data in these case notifications that CDC receives are collected by staff working on reportable disease and condition surveillance systems in local, state, and territorial health departments. Case notification of nationally notifiable infectious diseases and conditions helps public health authorities monitor the effect of these diseases and conditions, measure the disease and condition trends, assess the effectiveness of control and prevention measures, identify populations or geographic areas at high risk, allocate resources appropriately, formulate prevention strategies, and develop public health policies.
The list of nationally notifiable infectious diseases and conditions is revised periodically (Box 1). An infectious disease or condition might be added to the list as a new pathogen emerges, or a disease or condition might be removed as its incidence declines. Public health officials at state and territorial health departments collaborate with CDC staff in determining which infectious diseases and conditions should be considered nationally notifiable. CSTE, with input from CDC, makes recommendations annually for additions and deletions to the list. The list of infectious diseases and conditions considered reportable in each jurisdiction varies over time and across jurisdictions. Current and historic national public health surveillance case definitions used for classifying and enumerating cases consistently at the national level across reporting jurisdictions are available at

Data Sources

Provisional data on the reported occurrence of nationally notifiable infectious diseases and conditions are published weekly in MMWR. After each reporting year, staff in state and territory health departments finalize reports of cases for that year with local or county health departments and reconcile the data with reports previously sent to CDC throughout the year. These data are compiled in final form in this summary, which represents the official and archival counts of cases for each year. The data in these reports are approved by the appropriate chief epidemiologist from each submitting state or territory before being published in this summary. Data published in MMWR Surveillance Summaries or other surveillance reports produced by CDC programs might differ from data reported in this summary because of differences in the timing of reports, the source of the data, or surveillance methodology.
Data in this summary were derived primarily from reports transmitted to CDC from health departments in the 50 states, five territories, New York City, and the District of Columbia (reporting jurisdictions). Data were reported for MMWR weeks 1–53, which correspond to the period for the week ending January 4, 2014 through the week ending January 3, 2015. More information regarding notifiable infectious diseases and conditions, including national surveillance case definitions, is available at Policies for reporting notifiable infectious disease and condition cases can vary by disease, condition, or reporting jurisdiction. The case-status categories used to determine which cases reported to NNDSS are published in the tables are listed by infectious disease or condition in the publication criteria column of the 2014 NNDSS event code list (Box 2).
For a report of a nationally notifiable disease or condition to be published in MMWR (formerly described as “print criteria” and currently described as “publication criteria”), the reporting state or territory must have designated the infectious disease or condition reportable in their state or territory for the year corresponding to the year of report to CDC. After this criterion is met, the infectious disease- or condition-specific criteria listed in the Exhibit are applied. Where the Exhibit indicates that all reports will be published, this means that cases designated with unknown or suspect case confirmation status will be included in the counts along with probable and confirmed cases. Data for new nationally notifiable infectious diseases or conditions are not usually available from reporting jurisdictions until January of the year following the approval of the CSTE position statement. In addition, CDC must have Office of Management and Budget Paperwork Reduction Act approval to request data from reporting jurisdictions (1). As a result, there is usually a delay between the time CSTE recommends a condition be made nationally notifiable and the time CDC can aggregate the data submitted by reporting jurisdictions.
Final data for certain infectious diseases and conditions are derived from the surveillance records of the CDC program. Requests for further information regarding these data should be directed to the appropriate program. The CDC organization responsible for finalizing the data used for the final MMWR tables for each condition is listed in the Exhibit.
Population estimates were obtained from the NCHS postcensal estimates of the resident population of the United States during July 1, 2013–July 1, 2014, by year, county, single year of age (range: 0 to ≥85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2014), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 25, 2015 are available at Population estimates for territories are from the 2014 U.S. Census Bureau International Data Base, available at The choice of population denominators for incidence reported in MMWR is based on the availability of census population data at the time of preparation for publication and the desire for consistent use of the same population data to compute incidence reported by different CDC programs.
Incidence in this summary was calculated as the number of reported cases for each infectious disease or condition divided by either the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. For Territories, incidence in this summary was calculated as the number of reported cases for each infectious disease or condition divided by either the territorial resident population for the specified demographic population or the total territorial resident population, multiplied by 100,000. When a nationally notifiable infectious disease or condition is associated with a specific age restriction, the same age restriction was applied to the population in the denominator of the incidence calculation. In addition, population data from states in which the disease or condition was not reportable or was not available are excluded from incidence calculations. Unless otherwise stated, disease totals for the United States do not include data for American Samoa, Guam, Puerto Rico, the Commonwealth of the Northern Mariana Islands, or the U.S. Virgin Islands.

Interpreting Data

The completeness of information on notifiable infectious diseases and conditions was highly variable and related to the disease or condition being reported (29). Incidence data in this summary are presented by the MMWR week and year ( assigned by the state or territorial health department, with some exceptions, including human immunodeficiency virus (HIV) (presented by date of diagnosis), tuberculosis (presented by date CDC surveillance staff verified that the case met the criteria in the national surveillance case definition), domestic arboviral diseases (presented by date of illness onset), and varicella deaths (presented by date of death). Data were reported by the jurisdiction of the person’s “usual residence” at the time of disease or condition onset ( For certain nationally notifiable infectious diseases and conditions, surveillance data are reported independently to various CDC programs. For this reason, surveillance data reported by other CDC programs might vary from data reported in this summary because of differences in 1) the date used to aggregate data (e.g., date of report or date of disease or condition occurrence), 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC). In addition, the “date of disease occurrence” of conditions might vary. For infectious diseases, the meaning of the “date of disease occurrence” varies across jurisdictions and by disease and might be a date of symptom or disease onset, diagnosis, laboratory result, reporting of a case to a jurisdiction, or notification of a case to CDC.
Data reported in this summary are useful for analyzing infectious disease or condition trends and determining relative infectious disease or condition numbers. However, reporting practices affect how these data should be interpreted. Infectious disease and condition reporting is likely incomplete, and completeness might vary depending on the infectious disease or condition and reporting state. The degree of completeness of data reporting also might be influenced by the diagnostic facilities available, control measures in effect, public awareness of a specific infectious disease or condition, and the resources and priorities of state and local officials responsible for public health surveillance and for controlling infectious diseases and conditions. Finally, factors such as changes in methods for public health surveillance, introduction of new diagnostic tests, or discovery of new infectious disease or condition entities can cause changes in reporting that are independent of the actual incidence of infectious disease or condition.
Public health surveillance data are published for selected racial/ethnic populations because these characteristics can be risk markers for certain notifiable infectious diseases or conditions. Race and ethnicity data also can be used to highlight populations for focused prevention programs. However, caution must be used when drawing conclusions from reported race and ethnicity. Different racial/ethnic populations might have different patterns of access to health care, potentially resulting in data that are not representative of actual infectious disease or condition incidence among specific population groups. In addition, not all race and ethnicity data are collected or reported uniformly for all infectious diseases and conditions; for example, the recommended standard for classifying a person’s race or ethnicity is based on self-reporting. However, this procedure might not always be followed.
Surveillance data reported to NNDSS are in either individual case-specific form or summary form (i.e., aggregated data for a group of cases). Summary data often lack demographic information (e.g., race); therefore, the demographic-specific rates presented in this summary might be underestimated.

Transitions in NNDSS Data Collection

Data collection in NNDSS has undergone various transitions over time. Before 1990, data were reported to CDC as cumulative counts rather than as individual case reports. In 1990, using the National Electronic Telecommunications System for Surveillance (or NETSS), states began electronically capturing and reporting individual cases to CDC without personal identifiers. In 2001, CDC launched the National Electronic Disease Surveillance System (NEDSS) to promote the use of data and information system standards that advance the development of efficient, integrated, and interoperable surveillance information systems at the local, state, territorial, and national levels. Reporting jurisdictions now use integrated surveillance information systems based on NEDSS architectural standards to submit NNDSS data to CDC. Additional information concerning NEDSS is available at
In 2013, CDC began to conceptualize improvements to strengthen and modernize the technical infrastructure supporting NNDSS. In 2014, CDC and selected states began work on the NNDSS Modernization Initiative (NMI), a multiyear commitment to enhance NNDSS surveillance capabilities. An important benefit for public health decision making will be the ability to acquire higher quality data that are more comprehensive and timely. Through NMI, CDC and its state partners will increase the robustness of the NNDSS technological infrastructure so that it is based on interoperable, standardized data and data exchange mechanisms. Additional information is available at

Method for Identifying which Nationally Notifiable Infectious Diseases and Conditions are Reportable

States and jurisdictions are sovereign entities. Reportable conditions are determined by the laws and regulations of each state, territory, or local jurisdiction. Some infectious diseases and conditions deemed nationally notifiable by CSTE might not be designated as reportable in certain states or jurisdictions. Only data from reporting states, territories, and jurisdictions that designated the infectious disease or condition as reportable are included in the summary tables. This ensures the data displayed in this summary are from population-based surveillance efforts and are generally comparable across states, territories, and other jurisdictions. When a CSTE- and CDC-recommended nationally notifiable disease or condition is not reportable by state, territory, or other jurisdiction officials, an “N” indicator for “not reportable” is inserted in the table for the specified reporting state, territory, or jurisdiction and applicable year. Each year, the NNDSS Data Processing Team solicits information from each NNDSS reporting state, territory, and jurisdiction (all 50 U.S. states, the District of Columbia, New York City, and five U.S. territories) about whether reporting is mandated by law or regulation for each nationally notifiable condition.

International Health Regulations

At its annual meeting in June 2007, CSTE approved a position statement that supports implementation of International Health Regulations (IHR) in the United States (10). CSTE approval followed the adoption of revised IHR in May 2005 by the World Health Assembly (11) that went into effect in the United States on July 18, 2007. This international legal instrument governs the role of the World Health Organization (WHO) and its member countries, including the United States, in identifying, responding to, and sharing information about events that might constitute a Public Health Emergency of International Concern (PHEIC). A PHEIC is an extraordinary event that constitutes a public health risk to other countries through international spread of disease and potentially requires a coordinated international response. All WHO member countries are required to notify WHO of a potential PHEIC. WHO makes the final determination about the existence of a PHEIC.
Health care providers in the United States are required to report diseases, conditions, and outbreaks determined to be reportable by local, state, or territorial law or regulation. In addition, all health care providers should work with their local, state, or territorial health agencies to identify and report events occurring in their location that might constitute a PHEIC. U.S. state and territorial departments of health report information about a potential PHEIC to the most relevant federal agency responsible for monitoring such an event. In the case of human infectious disease, the U.S. state or territorial departments of health notifies CDC through existing formal and informal reporting mechanisms (10). CDC further analyzes the event by use of the decision algorithm in Annex 2 of the IHR and notifies the U.S. Department of Health and Human Services (HHS) Secretary’s Operations Center (SOC), as appropriate. The HHS SOC is responsible for reporting a potential PHEIC to WHO.
In the United States, HHS has the lead role in carrying out IHR, in cooperation with multiple federal departments and agencies. When a potential PHEIC is identified, the United States has 48 hours to assess the risk of the reported event. If authorities determine that a potential PHEIC exists, the United States, as with all WHO member countries, has 24 hours to report the event to WHO. The HHS SOC is responsible for reporting a potential PHEIC to WHO.
An IHR decision algorithm (Annex 2 of the IHR) was developed to help countries determine whether an event should be reported. If any two of the following four questions are answered in the affirmative, then a potential PHEIC exists and WHO should be notified:
  • Is the public health impact of the event serious?
  • Is the event unusual or unexpected?
  • Is there a significant risk of international spread?
  • Is there a significant risk for international travel or trade restrictions?
The revised IHR reflects a conceptual shift from the use of a predefined disease list to a framework of reporting and responding to events on the basis of an assessment of public health criteria, including seriousness, unexpectedness, and international travel and trade implications. A PHEIC is an event that falls within those criteria (further defined in a decision algorithm in Annex 2 of the revised IHR); however, any one of the following four conditions always constitutes a PHEIC and do not require the use of the IHR decision instrument in Annex 2:
  • severe acute respiratory syndrome (SARS),
  • smallpox,
  • poliomyelitis caused by wild-type poliovirus, and
  • human influenza caused by a new subtype.
Examples of events that require the use of the decision instrument include, but are not limited to cholera, pneumonic plague, yellow fever, West Nile fever, viral hemorrhagic fevers, and meningococcal disease. Other biologic, chemical, or radiologic events that fit the decision algorithm also must be reported to WHO.
Additional information about IHR is available at, and CSTE also approved a position statement that added initial detections of novel influenza A virus infections to the list of nationally notifiable infectious diseases, beginning in January 2007, to in part support the implementation of the revised IHR in the United States to identify human influenza caused by a new subtype (12).


We acknowledge all the local, state, and territorial health departments in the United States for collecting the data included in this report from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and for reporting these data to CDC.


  1. U.S. Department of Health and Human Services. Information Collection and Paperwork Reduction Act (PRA) overview. Washington, DC: U.S. Department of Health and Human Services; 2015.
  2. Doyle TJ, Glynn MK, Groseclose SL. Completeness of notifiable infectious disease reporting in the United States: an analytical literature review. Am J Epidemiol 2002;155:866–74. aje/155.9.866
  3. CDC. Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data—United States. MMWR Morb Mortal Wkly Rep 2011;60:410–3. 
  4. CDC. Evaluation of acute hepatitis C infection surveillance— United States, 2008. MMWR Morb Mortal Wkly Rep 2010;59:1407–10. 
  5. Hwang J, McClintock S, Kachur SP, Slutsker L, Arguin P. Comparison of national malaria surveillance system with the national notifiable diseases surveillance system in the United States. J Public Health Manag Pract 2009;15:345–51. 
  6. Painter JE, Hlavsa MC, Collier SA, Xiao L,Yoder JS. Cryptosporidiosis surveillance—United States, 2011–2012. MMWR Surveill Summ 2015;64(No. SS-3). 
  7. Painter JE, Gargano JW, Collier SA, Yoder JS. Giardiasis surveillance— United States, 2011–2012. MMWR Suppl 2015;64(No SS-3):15–25. 
  8. Wilson NO, Hall RL, Montgomery SP, Jones JL. Trichinellosis surveillance—United States, 2008–2012. MMWR Surveill Summ 2015;64(No. SS-1):1–8. 
  9. CDC. Babesiosis surveillance—18 States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:505–9. 
  10. Council of State and Territorial Epidemiologists. Events that may constitute a public health emergency of international concern. Position statement 07-ID-06. resmgr/PS/07-ID-06.pdf
  11. World Health Organization. International Health Regulations, Second ed. Geneva, Switzerland: World Health Organization; 2005. eng.pdf
  12. Council of State and Territorial Epidemiologists. Council of State and Territorial Epidemiologists position statement; 2007. National reporting for initial detections of novel influenza A viruses. sites/
* No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe acute respiratory syndrome-associated Coronavirus disease (SARS-CoV); smallpox; vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis, neuroinvasive and nonneuroinvasive disease; and yellow fever were reported in the United States during 2014.
Return to your place in the textBOX 1Infectious Diseases and Conditions Designated by CSTE and CDC as Nationally Notifiable During 2014*
Arboviral diseases, neuroinvasive and nonneuroinvasive
   California serogroup viruses
   Eastern equine encephalitis virus
   Powassan virus
   St. Louis encephalitis virus
   West Nile virus
   Western equine encephalitis virus
   Other (includes wound and unspecified)
Chlamydia trachomatis infection
Cholera (Vibrio cholerae O1 or O139)
Dengue virus infections
   Dengue fever
   Dengue hemorrhagic fever
   Dengue shock syndrome
   Anaplasma phagocytophilum infection
   Ehrlichia chaffeensis infection
   Ehrlichia ewingii infection
   Undetermined human ehrlichiosis/anaplasmosis
Haemophilus influenzae, invasive disease
Hansen’s disease (Leprosy)
Hantavirus pulmonary syndrome
Hemolytic uremic syndrome, postdiarrheal
Hepatitis, viral
   Hepatitis A, acute
   Hepatitis B, acute
   Hepatitis B, chronic
   Hepatitis B, perinatal infection
   Hepatitis C, acute
   Hepatitis C, past or present
Human Immunodeficiency Virus (HIV) diagnoses§
Influenza-associated pediatric mortality
Invasive pneumococcal disease (Streptococcus pneumoniae, invasive disease)
Legionellosis (Legionnaire’s Disease or Pontiac fever)
Lyme disease
Meningococcal disease (Neisseria meningitidis)
Novel influenza A virus infections
Poliomyelitis, paralytic
Poliovirus infection, nonparalytic
Q fever
Rubella, congenital syndrome
Severe acute respiratory syndrome-associated coronavirus disease (SARS-CoV)
Shiga toxin-producing Escherichia coli (STEC)
Spotted fever rickettsiosis
Streptococcal toxic shock syndrome
Syphilis, congenital
Toxic shock syndrome (other than streptococcal)
Typhoid fever (caused by Salmonella enterica serotype Typhi)
Vancomycin-intermediate Staphylococcus aureus (VISA) infection
Vancomycin-resistant Staphylococcus aureus (VRSA) infection
Varicella (morbidity)
Varicella (mortality)
Vibriosis (any species of the family Vibrionaceae, other than toxigenic Vibrio cholerae O1 or O139)
Viral Hemorrhagic Fever
   Crimean-Congo Hemorrhagic fever virus
   Ebola virus
   Lassa virus
   Lujo virus
   Marburg virus
   New World Arenaviruses (Guanarito, Machupo, Junin, and Sabia viruses)
Yellow fever
* This list reflects position statements approved in 2013 (or 2012, in the case of leptospirosis) by the Council of State and Territorial Epidemiologists (CSTE) for national surveillance, which were implemented in January 2014. In 2012, CSTE recommended that Leptospirosis be made nationally notifiable, but because of delays in Office of Management and Budget Paperwork Reduction Act approval, it was not added to the list of nationally notifiable conditions until 2014. National surveillance case definitions for these infectious diseases and conditions are available at
 The year 2014 reflects a modified surveillance case definition for this disease per approved 2013 CSTE position statements.
§ AIDS (Acquired Immunodeficiency Syndrome) has been reclassified as HIV stage III.
 Includes the following categories: primary, secondary, latent (including early latent and late latent) and late syphilis with clinical manifestations (including late benign syphilis and cardiovascular syphilis).
Return to your place in the textBOX 2EXHIBIT: Publication criteria and CDC organization responsible for finalizing the data with reporting jurisdictions for notifiable conditions reported to the National Notifiable Diseases Surveillance System, 2014
CodeNotifiable conditionPublication criteria*,,§CDC Organization responsible for finalizing the data
11090Anaplasma phagocytophilumConfirmed and probableOPHSS
10350AnthraxConfirmed and probableOPHSS
12010BabesiosisConfirmed and probableOPHSS
10530Botulism, foodborneConfirmedOPHSS
10540Botulism, infantConfirmedOPHSS
10550Botulism, other (includes wound)ConfirmedOPHSS
10548Botulism, other (unspecified)ConfirmedOPHSS
10549Botulism, woundConfirmedOPHSS
10020BrucellosisConfirmed and probableOPHSS
10054California serogroup virus disease, neuroinvasiveConfirmed and probableNCEZID; DVBD
10061California serogroup virus disease, nonneuroinvasiveConfirmed and probableNCEZID; DVBD
10273ChancroidAll reportsNCHHSTP; DSTDP
10274Chlamydia trachomatis infectionAll reportsNCHHSTP; DSTDP
10470Cholera (toxigenic Vibrio cholerae O1 or O139)ConfirmedOPHSS
11580CryptosporidiosisConfirmed and probableOPHSS
11575CyclosporiasisConfirmed and probableOPHSS
10680Dengue fever (DF)Confirmed and probableNCEZID; DVBD
10685Dengue hemorrhagic fever (DHF) (and Dengue shock syndrome (DSS)Confirmed and probableNCEZID; DVBD
10040DiphtheriaConfirmed, probable, and unknownOPHSS
10053Eastern equine encephalitis virus disease, neuroinvasiveConfirmed and probableNCEZID; DVBD
10062Eastern equine encephalitis virus disease, nonneuroinvasiveConfirmed and probableNCEZID; DVBD
11088Ehrlichia chaffeensisConfirmed and probableOPHSS
11089Ehrlichia ewingiiConfirmed and probableOPHSS
11091Ehrlichiosis/Anaplasmosis, undeterminedConfirmed and probableOPHSS
11570GiardiasisConfirmed and probableOPHSS
10280GonorrheaAll reportsNCHHSTP; DSTDP
10590Haemophilus influenzae, invasive diseaseConfirmed, probable, and unknownOPHSS
10380Hansen’s disease (leprosy)ConfirmedOPHSS
11590Hantavirus pulmonary syndrome (HPS)ConfirmedNCEZID; DHCPP
11550Hemolytic uremic syndrome, postdiarrheal (HUS)Confirmed and probableOPHSS
10110Hepatitis A, acuteConfirmedNCHHSTP; DVH
10100Hepatitis B, acuteConfirmedNCHHSTP; DVH
10105Hepatitis B, chronicConfirmed and probableNCHHSTP; DVH
10104Hepatitis B perinatal infectionConfirmedNCHHSTP; DVH
10101Hepatitis C, acuteConfirmedNCHHSTP; DVH
10106Hepatitis C, past or presentConfirmed and probableNCHHSTP; DVH
 HIV diagnosesConfirmedNCHHSTP; DHAP
11061Influenza-associated pediatric mortalityConfirmedNCIRD; ID
11723Invasive Pneumococcal Disease (IPD)/Streptococcus pneumoniae,
invasive disease (all ages)
10390LeptospirosisConfirmed and probableOPHSS
11080Lyme diseaseConfirmed and probableOPHSS
10140Measles (rubeola), totalConfirmed and unknownOPHSS
10150Meningococcal disease (Neisseria meningitidis)Confirmed and probableOPHSS
10180MumpsConfirmed, probable, and unknownOPHSS
11062Novel influenza A virus infections, initial detections ofConfirmedNCIRD; ID
10190Pertussis (Whooping Cough)Confirmed, probable, and unknownOPHSS
10440PlagueAll reportsOPHSS
10410Poliomyelitis, paralyticConfirmedOPHSS
10405Poliovirus infection, nonparalyticConfirmedOPHSS
10057Powassan virus disease, neuroinvasiveConfirmed and probableNCEZID; DVBD
10063Powassan virus disease, nonneuroinvasiveConfirmed and probableNCEZID; DVBD
10450Psittacosis (Ornithosis)Confirmed and probableOPHSS
10257Q fever, acuteConfirmed and probableOPHSS
10258Q fever, chronicConfirmed and probableOPHSS
10340Rabies, animalConfirmedNCEZID; DHCPP
10460Rabies, humanConfirmedNCEZID; DHCPP
10200RubellaConfirmed and unknownOPHSS
10370Rubella, congenital syndrome (CRS)Confirmed, probable, and unknownOPHSS
11000SalmonellosisConfirmed and probableOPHSS
10575Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) diseaseConfirmed and probableOPHSS
11563Shiga toxin-producing Escherichia coli (STEC)Confirmed and probableOPHSS
11010ShigellosisConfirmed and probableOPHSS
11800SmallpoxConfirmed and probableOPHSS
10250Spotted fever rickettsiosisConfirmed, probable, and unknownOPHSS
10051St. Louis encephalitis virus disease, neuroinvasiveConfirmed and probableNCEZID; DVBD
10064St. Louis encephalitis virus disease, nonneuroinvasiveConfirmed and probableNCEZID; DVBD
11700Streptococcal toxic shock syndrome (STSS)Confirmed and probableOPHSS
10316Syphilis, congenitalAll reportsNCHHSTP; DSTDP
10313Syphilis, early latentAll reportsNCHHSTP; DSTDP
10314Syphilis, late latentAll reportsNCHHSTP; DSTDP
10319Syphilis, late with clinical manifestations (including late benign syphilis and cardiovascular syphilis)All reportsNCHHSTP; DSTDP
10311Syphilis, primaryAll reportsNCHHSTP; DSTDP
10312Syphilis, secondaryAll reportsNCHHSTP; DSTDP
10310Syphilis, total primary and secondaryAll reportsNCHHSTP; DSTDP
10210TetanusAll reportsOPHSS
10520Toxic shock syndrome (staphylococcal) (TSS)Confirmed and probableOPHSS
10270TrichinellosisConfirmed and probableOPHSS
10220TuberculosisConfirmedNCHHSTP; DTE
10230TularemiaConfirmed and probableOPHSS
10240Typhoid fever (caused by Salmonella typhi)Confirmed and probableOPHSS
11663Vancomycin-intermediate Staphylococcus aureus (VISA)ConfirmedOPHSS
11665Vancomycin-resistant Staphylococcus aureus (VRSA)ConfirmedOPHSS
10030Varicella morbidity (Chickenpox)Confirmed and probableOPHSS
 Varicella mortalityConfirmed and probableNCIRD; DVD
11545Vibriosis (any species of the family Vibrionaceae, other than toxigenic
Vibrio cholerae O1 or O139)
Confirmed and probableOPHSS
11647Viral hemorrhagic fevers (VHF)ConfirmedOPHSS
10056West Nile virus disease, neuroinvasiveConfirmed and probableNCEZID; DVBD
10049West Nile virus disease, nonneuroinvasiveConfirmed and probableNCEZID; DVBD
10052Western equine encephalitis virus disease, neuroinvasiveConfirmed and probableNCEZID; DVBD
10065Western equine encephalitis virus disease, nonneuroinvasiveConfirmed and probableNCEZID; DVBD
10660Yellow feverConfirmed and probableNCEZID; DVBD
Abbreviations: OPHSS = Office of Public Health Scientific Services; NCEZID = National Center for Emerging and Zoonotic Infectious Diseases; DVBD = Division of Vector-Borne Diseases; NCHHSTP = National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention; DSTDP = Division of STD Prevention; DHCPP = Division of High Consequence Pathogens and Pathology; DVH = Division of Viral Hepatitis; DHAP = Division of HIV/AIDS Prevention; NCIRD = National Center for Infectious and Respiratory Diseases; ID = Influenza Division; DTE = Division of Tuberculosis Elimination; DVD = Division of Viral Diseases.
* An unknown case classification status is used when a reporting jurisdiction sends aggregate counts of cases or when the surveillance information system of a reporting jurisdiction does not capture case classification data. In both situations, cases are verified to meet the case classification (e.g., confirmed, probable, and suspected) specified in the publication criteria.
† Publication criteria for the National Notifiable Diseases Surveillance System (NNDSS): for a case report of a nationally notifiable disease to be published in MMWR, the reporting state or territory must have designated the disease reportable in their state or territory for the year corresponding to the year of report to CDC. After this criterion is met, the disease-specific criteria listed in the Exhibit are applied. When the above-listed table indicates that all reports will be earmarked for publication, this means that cases designated with unknown or suspect case confirmation status will be published just as probable and confirmed cases will be published. Because Council of State and Territorial (CSTE) position statements customarily are not finalized until July of each year, NNDSS data for the newly added conditions usually are not available from all reporting jurisdictions until January of the year following the approval of the CSTE position statement.
§ Based on case classification status.
 Publication criteria determined by reporting jurisdictions. In 2014 Varicella deaths were reported from four jurisdictions with the following publication criteria; Texas (probable), Florida (confirmed), Virginia (confirmed), and Georgia (confirmed).

Nationally Notifiable Infectious Conditions Group

Paul M. Arguin, MD; Aileen Artus, MPH; Kaitlin Benedict, MPH; David D. Blaney, MD; Jesse Blanton, MPH; Anna Bowen, MD; William A. Bower, MD; Elizabeth C. Briere, MD; Kevin Chatham-Stephens, MD; Tom Chiller, MD; Mary Choi, MD; Nakia Clemmons, MPH; Shannon Cooney, MPH; Karen A. Cullen, PhD; F. Scott Dahlgren, MSPH; Annabelle de St Maurice, MD; Naomi Drexler, MPH; Elizabeth Ervin, MPH; Amanda E. Faulkner, MPH; Marc Fischer, MD; Kathleen E. Fullerton, MPH; Julia Warner Gargano, PhD; Laurel E. Garrison, MPH; Hannah Gould, PhD; Elizabeth B. Gray, MPH; Marta Guerra, DVM; Rebecca Hall, MPH; Kristen Nichols Heitman, MPH; Katherine A. Hendricks, MD; Barbara L. Herwaldt, MD; Michele C. Hlavsa, MPH; Scott Holmberg, MD; Jacqueline Hurd, MPH; Martha Iwamoto, MD; Kelly A. Jackson, MPH; Ruth Jiles, PhD; Anna Satcher Johnson, MPH; Jeffrey Jones, MD; Michael Judd, MPH; Grishma A. Kharod, MPH; Sarah Kidd, MD; Robert Kirkcaldy, MD; Barbara Knust, DVM; Kiersten J. Kugeler, PhD; Ben Kupronis, MPH; Amanda N. Lankford; Jennifer Lehman; Nicole Lindsey, MPH; Adriana Lopez, MHS; Kimberly E. Mace, PhD; Jessica R. MacNeil, MPH; Barbara Mahon, MD; Lilia P. Manangan, MPH; Stacey W. Martin, MSc; Robert F. Massung, PhD; Orion McCotter, MPH; Paul S. Mead, MD; Rajal K. Mody, MD; Susan Montgomery, DVM; Anna Newton, MPH; Christopher D. Paddock, MD; Emily Pieracci, DVM; Robert H. Pratt; Rodney Presley, PhD; Lawrence Purpura, MD; Susan Redd; Pierre Rollin, MD; Ilana J. Schafer, DVM; Sean V. Shadomy, DVM; Tyler M. Sharp, PhD; Tami H. Skoff, MS; Erin Staples, MD; Tara Stine, PhD; Tejpratap S.P. Tiwari, MD; Elizabeth Torrone, PhD; Rita M. Traxler, MHS; Gregory Wallace, MD; Ryan Wallace, DVM; Hillard Weinstock, MD; Emily Weston, MPH, CDC.

Highlights for 2014


The U.S. Food and Drug Administration (FDA) has approved two antitoxin treatments for inhalation anthrax: anthrax immune globulin intravenous (human) (i.e., Anthrasil) (1) and raxibacumab (2). These therapeutics are held in the Strategic National Stockpile, and requests for use must be made to CDC. Antitoxins, in combination with antimicrobials and supportive therapies, are recommended for treatment of systemic anthrax. In addition, anthrax vaccine adsorbed (i.e., BioThrax) is FDA-approved as a 3-dose postexposure prophylaxis (PEP) series, along with antimicrobials, to prevent anthrax in adults exposed to Bacillus anthracis (3). PEP and treatment recommendations exist for multiple populations, including children, pregnant and postpartum women, and adults for conventional and mass casualty settings (47).
  1. Food and Drug Administration. FDA approves treatment for inhalation anthrax. 2015.
  2. Food and Drug Administration. FDA approves raxibacumab to treat inhalational anthrax. 2012.
  3. Food and Drug Administration. FDA approves vaccine for use after known or suspected anthrax exposure. 2015.
  4. Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014;133:e1411–36. CrossRef PubMed
  5. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014;20: . CrossRef PubMed
  6. Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 2014;20: . CrossRef PubMed
  7. Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 2015;64(No. RR-4 ). PubMed

Domestic Arboviral Disease, Neuroinvasive and Nonneuroinvasive

In 2014, a total of 2,205 West Nile virus (WNV) disease cases were reported, including 1,347 cases of neuroinvasive disease (e.g., meningitis, encephalitis, and acute flaccid paralysis) and 97 deaths (1). WNV disease cases were reported from 42 states and the District of Columbia. Three states reported two thirds (66%) of the WNV neuroinvasive disease cases: California (561 cases), Texas (253), and Arizona (80). The incidence of neuroinvasive disease was similar to the median incidence during 2002–2013 (median = 0.40; range = 0.13–1.02). However, California reported a record 561 neuroinvasive disease cases, 83% more than the next highest year (2005). In California, 70% of all neuroinvasive disease cases were reported from two counties (Los Angeles and Orange). These findings underscore the focal nature of WNV outbreaks.
After WNV, the next most commonly reported cause of neuroinvasive arboviral disease was La Crosse virus, followed by Jamestown Canyon virus, St. Louis encephalitis virus, Powassan virus, and Eastern equine encephalitis virus. Jamestown Canyon virus disease cases continue to be reported from new locations (e.g., Tennessee) following the implementation of routine Jamestown Canyon virus antibody testing at CDC in 2013 (2). Although rare, Eastern equine encephalitis virus disease remained the most severe arboviral disease, with two deaths among eight patients.
  1. Lindsey NP, Lehman JA, Staples JE, Fischer M. West Nile virus and other nationally notifiable arboviral diseases—United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:929–34. CrossRef PubMed
  2. Pastula DM, Hoang Johnson DK, White JL, Dupuis AP , Fischer M, Staples JE. Jamestown Canyon virus disease in the United States—2000–2013. Am J Trop Med Hyg 2015;93:384–9. CrossRef PubMed


Babesiosis is caused by protozoan parasites of the genus Babesia, which infect red blood cells. Babesia infection can range from asymptomatic to life threatening. Clinical manifestations can include fever, chills, other nonspecific influenza-like symptoms, and hemolytic anemia. Babesia parasites usually are tickborne but also can be transmitted via blood transfusion or congenitally (1).
In 2014, a total of 1,744* cases of babesiosis were reported to CDC. Babesiosis cases were reported by 22 of the 31 states in which babesiosis was a reportable condition; 94% (1,636) of the reported cases occurred in residents of seven states (Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin). The median age of patients was 63 years (range: <1–96 years); 65% (1,131) were male, and sex was unknown for <1% (six). Among the 1,340 patients for whom data were available, 84% (1,124) had symptom onset dates during June–August.
  1. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011;155:509–19. CrossRef PubMed
* This number differs slightly from the denominator of 1,760 presented in table 2, which includes 22 erroneous reports not retracted before the deadline for finalizing the data. In addition, six cases that were reported after the deadline are included at the request of the pertinent health departments.


Botulism is a severe paralytic illness caused by toxins produced by Clostridium botulinum. Exposure to the toxin can occur by ingestion (foodborne botulism), in situ production from C. botulinumcolonization of either a wound (wound botulism) or the gastrointestinal tract (infant botulism and adult intestinal colonization botulism), or overdose of botulinum toxin used for cosmetic or therapeutic purposes (1). In 2014, a total of 161 cases of botulism were reported, including 127 cases in infants, 15 foodborne cases, and 19 cases classified as other, including wound botulism. During 2014, four outbreaks (events with two or more cases) of foodborne botulism were reported. One outbreak was associated with stinkheads (fermented whitefish heads, a traditional Alaska Native food) (three cases), one with seal oil (three cases), one with home-canned tomato sauce (two cases), and one with pasta and jarred pesto (two cases). The jarred pesto was produced in a home kitchen, sold commercially, and then mixed with the pasta by one of the cases; the only leftovers available for testing were the pesto and pasta mixed together.
All states maintain 24-hour telephone services for reporting of botulism and other public health emergencies. Health care providers should report suspected botulism cases immediately to their state health departments. CDC maintains intensive surveillance for cases of botulism in the United States and provides consultation and antitoxin for suspected cases. State health departments can reach the CDC botulism duty officer on call 24 hours a day, 7 days a week via the CDC Emergency Operations Center (telephone: 770-488-7100).
  1. Sobel J. Botulism. Clin Infect Dis 2005;41:1167–73. CrossRef PubMed


During 2014, a total of 92 human brucellosis cases were reported in the United States; 58 were among men. Cases were distributed throughout the United States, with the South Atlantic and Pacific regions having the highest number of reported cases (19 and 25, respectively). Persons who consume raw (unpasteurized) dairy products might be at increased risk for exposure to Brucellaspp., which can cause brucellosis (1). Feral swine hunters also are considered an at-risk population (2).
  1. CDC. Risks from unpasteurized dairy products.
  2. CDC. Hunters risks.


Chlamydia trachomatis is the most commonly reported nationally notifiable infectious disease in the United States; 1,441,789 cases were reported to CDC in 2014. Following a slight decline during 2012–2013, the national rate of reported chlamydial infection increased 2.8% during 2013–2014,* from 443.5 to 456.1 per 100,000 population (1). Rates were highest among females aged 15–19 years (2,941.0 cases per 100,000 females) and 20–24 years (3,651.1). The rate among women aged 15–19 years increased steadily during 2000–2011, but decreased 4.4% during 2011–2012, 7.9% during 2012–2013, and 4.2% during 2013–2014. As in previous years, rates of reported chlamydia were highest among non-Hispanic blacks. The rate of reported chlamydia among black females aged 15–19 years was 4.9 times the rate among white females in the same age group. Most chlamydial infections are asymptomatic, and rates of reported cases are affected by the diagnostic test used and the proportion of the population screened. Consequently, increases in case rates might reflect expanded screening coverage, use of more sensitive diagnostic tests, and increases in incidence of infection. Likewise, decreases in rates of reported chlamydial infections might suggest decreases in incidence of infection or decreases in screening coverage.
  1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.
* Rates for 2014 were calculated using the 2013 population estimates and differ from 2014 rates presented in the figures and table 7 (calculated using 2014 population estimates).


Cholera continues to be rare in the United States and is most often acquired during travel in countries where toxigenic Vibrio cholerae O1 or O139 is circulating (13). Of the five cholera infections in 2014, all were travel-associated (two with travel to Cuba, two to India, and one to Ghana). Although cholera is endemic in many African countries, the patient who traveled to Ghana is the first since 2011 to be associated with travel to an African country (4).
  1. Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG, Mintz ED. Cholera in the United States, 1995–2000: trends at the end of the twentieth century. J Infect Dis 2001;184:799–802.CrossRef PubMed
  2. Newton AE, Heiman KE, Schmitz A, et al. Cholera in United States associated with epidemic in Hispaniola. Emerg Infect Dis 2011;17:2166–8. CrossRef PubMed
  3. Loharikar A, Newton AE, Stroika S, et al. Cholera in the United States, 2001–2011: a reflection of patterns of global epidemiology and travel. Epidemiol Infect 2015;143:695–703. CrossRefPubMed
  4. Mintz ED, Guerrant RL. A lion in our village—the unconscionable tragedy of cholera in Africa. N Engl J Med 2009;360:1060–3. CrossRef PubMed


Coccidioidomycosis (i.e., Valley fever) is a fungal infection caused by inhalation of Coccidioides spp. spores that are present in the arid soil of the southwestern United States, California, and parts of Central and South America. Coccidioides also was recently identified in soil in south-central Washington in association with cases of human disease (1). After a substantial increase during 1998–2011 (2), the number of cases has decreased each year since then, including a 13% decrease in the number of cases from 2013 to 2014 (9,438 and 8,232, respectively). Historically, Arizona and California have had the highest number of reported coccidioidomycosis cases. Arizona, which reported the most cases (5,624) of any state in 2014, experienced a 4% decrease in the number of cases compared with 2013 (5,861 cases). California reported the second-highest number of cases (2,243) of any state in 2014 and experienced a 31% decrease compared with 2013 (3,272 cases).
Reasons for the overall decrease in reported cases might, in part, be related to changes in the environment or changes in the at-risk population. Physicians should continue to maintain a high suspicion for acute coccidioidomycosis in patients who live in or have traveled to areas in which the disease is endemic and should be aware of the possibility for coccidioidomycosis outside of its previously recognized geographic range.
  1. Litvintseva AP, Marsden-Haug N, Hurst S, et al. Valley fever: finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection. Clin Infect Dis 2015;60:e1–3 CrossRef PubMed
  2. CDC. Increase in reported coccidioidomycosis—United States, 1998–2011. MMWR Morb Mortal Wkly Rep 2013;62:217–21. PubMed


Approximately 95% of human cryptosporidiosis is caused by the numerous Cryptosporidium parvum and Cryptosporidium hominis subtypes. Although cryptosporidiosis affects persons of all age groups, cases are most frequently reported in children aged 1–4 years (1). A substantial increase in transmission of Cryptosporidium occurs during summer, coinciding with increased use of recreational water, a well-established risk factor for cryptosporidiosis. Cryptosporidium has emerged as the leading cause of nationally notified recreational water–associated outbreaks and waterborne disease outbreaks overall (2). Transmission through recreational water is facilitated by the substantial number (up to 108–109) of immediately infectious Cryptosporidium oocysts that can be shed in a single bowel movement (3), the extended time (days to weeks) that oocysts can be shed (4), the low (≤10 oocysts) infectious dose (5), and the extreme tolerance of Cryptosporidiumoocysts to chlorine (6). In 2014, the increased reporting observed after 2004 continued. In addition, the proportion of probable cases has increased to 36% of all reported cases, primarily because of changes in the 2011 and 2012 national case definitions.
Conventional diagnostics (e.g., microscopy and immunoassays) cannot discriminate among the Cryptosporidium species and their subtypes. CDC has launched CryptoNet, a molecular-based surveillance system that will integrate traditional and molecular data to help elucidate Cryptosporidium transmission pathways and thus the epidemiology of cryptosporidiosis in the United States. CryptoNet has successfully differentiated clusters of illness caused by different Cryptosporidium species and detected outbreaks caused by rare subtypes. Additional information about CryptoNet is available at
To reduce the burden of cryptosporidiosis associated with recreational water, enhanced prevention measures are needed. In the United States, public health codes for public aquatic facilities are written, enacted, implemented, and enforced by state or local officials; no federal agency regulates the design, construction, operation, and maintenance of these venues. To provide support to state and local jurisdictions, CDC led the development and revision of the Model Aquatic Health Code (MAHC) ( This guidance document integrates the latest science and best practices with specific code language and explanatory materials covering the design, construction, operation, and maintenance of public swimming pools, hot tubs/spas, and other aquatic venues. MAHC is updated every 2 years through an all-stakeholder–driven process via the Council for the Model Aquatic Health Code ( to ensure its continued relevance and to respond to the latest scientific data and aquatics sector innovations.
  1. Painter JE, Hlavsa MC, Collier SA, Xiao L, Yoder JS. Cryptosporidiosis surveillance—United States, 2011–2012. MMWR Suppl 2015;64(No. SS-3 ). PubMed
  2. Hlavsa MC, Roberts VA, Kahler AM, et al. Outbreaks of illness associated with recreational water—United States, 2011–2012. MMWR Morb Mortal Wkly Rep 2015;64:668–72. PubMed
  3. Goodgame RW, Genta RM, White AC, Chappell CL. Intensity of infection in AIDS-associated cryptosporidiosis. J Infect Dis 1993;167:704–9. CrossRef PubMed
  4. Chappell CL, Okhuysen PC, Sterling CR, DuPont HL. Cryptosporidium parvum : intensity of infection and oocyst excretion patterns in healthy volunteers. J Infect Dis 1996;173:232–6.CrossRef PubMed
  5. Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium hominis : experimental challenge of healthy adults. Am J Trop Med Hyg 2006;75:851–7. PubMed
  6. Murphy JL, Arrowood MJ, Lu X, Hlavsa MC, Beach MJ, Hill VR. Effect of cyanuric acid on the inactivation of Cryptosporidium parvum under hyperchlorination conditions. Environ Sci Technol 2015;49:7348–55. CrossRef PubMed


Of the 398 cyclosporiasis cases reported in 2014, a total of 275 (69%) were domestically acquired (i.e., they occurred in persons with no known history of travel outside the United States and Canada during the 14-day incubation period), 77 (19%) were associated with international travel, and 46 (12%) occurred in persons for whom the travel status was unknown or missing. Of the domestically acquired cases, 244 (89%) occurred in persons with onset of illness during May–August. Clusters of cases were identified in Michigan (June onset dates), Texas (June–July onsets), and South Carolina (July onsets) (1). In Michigan, a cluster of 14 cases identified among attendees of a conference included residents of Michigan and six other states. In Texas, 26 cluster-associated cases occurred among patrons of five different local Mexican-style restaurants. In South Carolina, one temporospatial cluster of 13 cases was investigated, although the exact location(s) of exposure was not identified. A vehicle of infection (i.e., fresh cilantro imported from Mexico) was implicated only for the 26 cluster-associated cases in Texas, marking the second consecutive year in which fresh cilantro from Mexico was implicated as the vehicle of infection for at least some of the reported cyclosporiasis cases in Texas. The vehicle(s) of infection was not identified for the remaining 218 (89% of 244) domestically acquired cases with onsets during May–August 2014. No molecular subtyping methods are available that could facilitate linking cases of cyclosporiasis to each other and to particular vehicles and sources of infection.
  1. CDC. U.S. foodborne outbreaks of cyclosporiasis—2000–2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2014.


Dengue is an acute febrile illness characterized by myalgia, headache, leukopenia, and minor bleeding manifestations (1). Patients with severe dengue experience plasma leakage resulting in fluid accumulation, hemorrhage, and/or major organ impairment (e.g., liver failure, myocarditis, and impaired consciousness). Dengue is endemic throughout much of the tropics and subtropics, where an estimated 50–100 million cases and 9,200 deaths occur annually (2). With proper clinical management, the case-fatality rate of hospitalized dengue patients can be <0.5% (3). Efforts to improve outcomes among persons with dengue include an online clinical education course developed by CDC (
In 2014, a total 680 laboratory-positive, travel-associated dengue cases were reported from 44 of the 50 states, two of the five territories, and the District of Columbia. Most (65%) persons with travel-associated dengue had a history of travel to the Caribbean or Americas, where chikungunya had recently emerged. Because dengue and chikungunya often have a similar clinical presentation, the increase in reported dengue cases compared to previous years, when dengue was not epidemic in the region, might be attributable to increased diagnostic testing to differentiate between these diseases among patients with acute febrile illness. The states with the most travel-associated dengue cases reported were California (130), Arizona (97), and Florida and New Jersey (84 each). Concomitant with a dengue epidemic in northern Mexico, an outbreak of travel-associated dengue occurred in Arizona, and all reported case-patients had recently traveled to Mexico; enhanced surveillance revealed no locally acquired cases (4). Florida reported seven locally acquired dengue cases. In the dengue-endemic Caribbean territories of Puerto Rico and the U.S. Virgin Island, reports of laboratory-positive dengue cases were substantially lower than in previous years (525 and 19 cases, respectively). No cases of dengue hemorrhagic fever were reported in 2014 in travelers or residents of U.S. territories.
  1. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva, Switzerland: World Health Organization; 2009.
  2. Stanaway JD, Shepard DS, Undurrage EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16:712–23.
  3. Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis 2013;57:1577–86.CrossRef PubMed
  4. Jones JM, Lopez B, Adams L, et al. Binational dengue outbreak along the United States–Mexico border—Yuma County, Arizona, and Sonora, Mexico, 2014. MMWR Morb Mortal Wkly Rep 2016;65:495–9. CrossRef PubMed


During 2014, a nonfatal case of diphtheria caused by nontoxigenic Corynebacterium diphtheriae was reported to CDC. The case occurred in a 17-year-old white female resident of Ohio. The patient was fully vaccinated. No other family member or close contact was ill.


Giardiasis is the most common enteric parasitic infection in the United States, infecting an estimated 1.2 million persons annually (1). Symptomatology is variable, but giardiasis is normally characterized by diarrhea, abdominal cramps, bloating, weight loss, and malabsorption; extraintestinal symptoms are possible (2). Infected persons can shed Giardia for several weeks, and recent studies indicate a potential for chronic sequelae from giardiasis (3). Giardia is endemic worldwide, including in the United States, and is the most commonly diagnosed pathogen among travelers returning to the United States from other countries (4). Giardia is commonly detected in internationally adopted children screened in the United States; often, these children do not have gastrointestinal symptoms (5). In 2014, the reported incidence of giardiasis appeared to decrease compared with 2013, which could reflect changes in reporting practices or changes in the actual occurrence of giardiasis.
Giardia is transmitted through the fecal-oral route with the ingestion of environmentally stable Giardia cysts. Most information on giardiasis transmission is from outbreak investigations; 242 giardiasis outbreaks reported to CDC for 1971–2011 resulted from waterborne (74.8%), foodborne (15.7%), person-to-person (2.5%) and animal contact (1.2%) transmission (6). On the basis of outbreak trends, investigators identified groundwater and distribution system vulnerabilities in drinking water systems, inadequate pool disinfection, fruit and vegetable contamination, and poor food handler hygiene as possible targets for giardiasis prevention measures. However, the majority of reported giardiasis cases are not linked to known outbreaks. Among reported cases, <2% are documented as outbreak-associated (7). An ecological study of sporadic giardiasis in the United States indicated that high county-level reliance on private wells was associated with higher giardiasis rates (8). Prospective epidemiologic studies and continued outbreak and case surveillance are needed to understand transmission pathways and to identify effective public health prevention measures.
Population studies of Giardia seroprevalence would contribute substantially to understanding the prevalence of giardiasis in the United States (9). Enhanced genotyping methods would increase knowledge of the molecular epidemiology of Giardia, including elucidating species-specific subassemblages (10). Application of these tools to epidemiologic studies and surveillance has the potential to improve understanding of giardiasis risk factors, enable researchers to identify outbreaks by linking cases currently classified as sporadic infections, and provide risk factor information needed to inform prevention strategies.
  1. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis 2011;17:7–15. CrossRef PubMed
  2. Cantey PT, Roy S, Lee B, et al. Study of nonoutbreak giardiasis: novel findings and implications for research. Am J Med 2011;124:1175.e1–8. CrossRef PubMed
  3. Hanevik K, Wensaas KA, Rortveit G, Eide GE, Mørch K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis 2014;59:1394–400. . CrossRef PubMed
  4. Harvey K, Esposito DH, Han P, et al. Surveillance for travel-related disease—GeoSentinel Surveillance System, United States, 1997–2011. MMWR Surveill Summ 2013;62(No. SS-9 ). PubMed
  5. Staat MA, Rice M, Donauer S, et al. Intestinal parasite screening in internationally adopted children: importance of multiple stool specimens. Pediatrics 2011;128:e613–22. PubMed
  6. Adam EA, Yoder JS, Gould H, Hlavsa MC. Giardiasis outbreaks in the United States, 1971–2011. Epidemiol Infect 2016.
  7. Schnell K, Collier S, Derado G, Yoder J, Gargano JW. Giardiasis in the United States—an epidemiologic and geospatial analysis of county-level drinking water and sanitation data, 1993–2010. J Water Health 2016;14:267–79. PubMed
  8. Yoder JS, Gargano JW, Wallace RM, Beach MJ Giardiasis surveillance—United States, 2009–2010. MMWR Surveill Summ 2012;61(No. SS-5 ). PubMed
  9. Priest JW, Moss DM, Visvesvara GS, Jones CC, Li A, Isaac-Renton JL. Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvumantigens. Clin Vaccine Immunol 2010;17:1695–707. CrossRef PubMed
  10. Feng Y, Xiao L. Zoonotic potential and molecular epidemiology of Giardia species and giardiasis. Clin Microbiol Rev 2011;24:110–40. CrossRef PubMed


Following a historically low rate in 2009 (98.1 cases per 100,000 population), the national rate of reported gonorrhea cases increased 12.8% to 110.7 in 2014* (1). The rate among men steadily increased during this period, including a 10.5% increase during 2013–2014; the rate among women decreased 0.4% during 2013–2014. The increase among men, coinciding with the decrease among women, suggests increased transmission and/or or increased case detection, including expanded extragenital gonorrhea screening, among gay, bisexual, and other men who have sex with men. As in previous years, the highest rates of gonorrhea were among persons aged 15–24 years, among non-Hispanic blacks, and in the South. In 2014, the gonorrhea rate among non-Hispanic blacks was 10.6 times the rate among non-Hispanic whites. Although the highest rate overall was in the South, including a 3.1% increase during 2013–2014, the rate of reported gonorrhea cases increased by 22.2% in the West during the same time.
Treatment for gonorrhea has been complicated by the repeated acquisition of antimicrobial resistance by Neisseria gonorrhoeae. The emergence of fluoroquinolone resistance during 2000–2007 and subsequent declining cefixime susceptibility (2006–2011) resulted in changes in the CDC treatment guidelines in 2007, 2010, and 2012. The only CDC-recommended treatment regimen for gonorrhea is dual therapy with intramuscular ceftriaxone and oral azithromycin (2). In CDC's sentinel surveillance system (Gonococcal Isolate Surveillance Project), the percentage of isolates with reduced cefixime susceptibility decreased from 1.4% in 2011 to 0.4% in 2013, and then increased to 0.8% in 2014. During this time, the percentage of isolates with elevated ceftriaxone minimum inhibitory concentrations (MICs) ranged from 0.05% (2013) to 0.4% (2011). During 2013–2014, the percentage with elevated azithromycin MICs increased from 0.6% to 2.5% (1).
  1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.
  2. CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3).
* Rates for 2014 were calculated using the 2013 population estimates and differ from 2014 rates presented in the figures and table 7 (calculated using 2014 population estimates).

Hansen’s Disease (Leprosy)

Hansen’s Disease (HD) (i.e., leprosy) is a chronic infectious disease caused by the obligate intracellular bacterium Mycobacterium leprae. Growing optimally at 27o–30o C (80.6o–86.0o F), HD primarily affects the skin and superficial peripheral nerves, most notably the posterior tibial and lateral popliteal nerves of the lower leg and foot, the ulnar, median, and radial nerves of the forearm and hand, and the facial nerve (1). HD is highly responsive to treatment but requires a prolonged multidrug therapy of 1–2 years of dapsone, rifampin, and clofazamine to result in cure (2). However, untreated disease can result in sensory and motor neuropathy, with eventual permanent disability of the eyes, hands, and feet (3).
An average of 89 HD cases have been reported to CDC per year since 2000, with a low of 66 in 2006 and a high of 105 in 2004; not all states list HD as a reportable disease, which might account for the higher numbers reported annually by the National Hansen’s Disease Programs (4). By race, white and Asian/Pacific Islanders accounted for the majority of new reported cases (36 [54%] of 67 cases and 24 [36%] of 67 cases, respectively). Similar to 2013, the majority of new cases in 2014 were reported from Texas (19 [22%] of 88), Hawaii (14 [16%] of 88), and New York City and Florida (10 [11%] of 88 each). In addition to the 88 cases reported in the United States, 13 cases were reported from Guam and two from Puerto Rico.
  1. Eichelmann K, González González SE, Salas-Alanis JC, Ocampo-Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr 2013;104:554–63. CrossRef PubMed
  2. Worobec SM. Current approaches and future directions in the treatment of leprosy. Res Rep Trop Med 2012;3:79–91. CrossRef
  3. Walker SL, Lockwood DNJ. Leprosy. Clin Dermatol 2007;25:165–72. CrossRef PubMed
  4. Hansen’s Disease Data & Statistics. Washington, DC: US Department of Health and Human Services; 2015.

Hantavirus Pulmonary Syndrome

Hantavirus pulmonary syndrome (HPS), a severe and sometimes fatal pulmonary disease resembling acute respiratory distress syndrome, is caused by hantavirus infection. Hantaviruses are transmitted by inhalation or direct contact with virus-containing particles or through direct contact with rodents who harbor the virus, such as the deer mouse (Peromyscus maniculatus). Most HPS cases occur in the western United States (1,2). In 2014, a total of 34* cases of HPS occurred in 13 states, of which 33 (97%) occurred in western states. Median age of patients was 38 years (range: 5–84). The 2014 case fatality rate was 38%, similar to previous reports.
Although HPS is a rare disease in the United States, it is associated with severe illness and high rates of death. Persons should avoid contact with deer mice or their droppings and use personal protective equipment when cleaning rodent infested environments.
  1. MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993–2009. Emerg Infect Dis 2011;17:1195–201. CrossRef PubMed
  2. Knust B, Rollin PE. Twenty-year summary of surveillance for human hantavirus infections, United States. Emerg Infect Dis 2013;19:1934–7. CrossRef PubMed
* Although 32 cases were reported in table 1, two cases were subsequently added.

Hemolytic Uremic Syndrome, Postdiarrheal

Hemolytic uremic syndrome (HUS) is characterized by the triad of hemolytic anemia, thrombocytopenia, and renal insufficiency. The most common etiology of postdiarrheal HUS in the United States is infection with Shiga toxin-producing Escherichia coli (STEC), principally STEC O157:H7 (1,2). Children aged <5 years progress to HUS more often than all other persons infected with STEC O157:H7 (15.3% vs. 6.3%) (3). In 2014, as in previous years of surveillance, the age group with the most reported cases was children aged 1‒4 years (117 of 250 cases).
  1. Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001;183:1063–70. CrossRef PubMed
  2. Mody RK, Luna-Gierke RE, Jones TF, et al. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 2012;166:902–9. CrossRef PubMed
  3. Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000–2006. Clin Infect Dis 2009;49:1480–5. CrossRef PubMed

Human Immunodeficiency Virus Infections

CDC requires states to report Human Immunodeficiency Virus Infections (HIV) case data through the enhanced HIV/AIDS Reporting System (eHARS), which is a browser-based system deployed at 54 state/local and territorial public health departments in the United States. HIV surveillance data are not reported through NNDSS. De-identified data are transmitted monthly from health departments through the secure access management system (SAMS) directly to CDC’s Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, and are incorporated into the National HIV Surveillance System database.
As of April 2008, all 50 states, the District of Columbia, and six U.S. dependent areas required confidential name-based reporting for HIV infection, in addition to reporting persons whose disease has been classified as stage 3 (acquired immunodeficiency syndrome [AIDS]). In 2008, CDC published a revised surveillance case definition for HIV infection that includes AIDS and incorporates the HIV infection classification (1). Laboratory-confirmed evidence of HIV infection is required to meet the surveillance case definition for HIV infection, including stage 3 (AIDS).
In 2014, the HIV surveillance case definition was revised to adapt to changes in diagnostic criteria used by laboratories and clinicians (2). The laboratory criteria for defining a confirmed case of HIV infection were changed to accommodate multitest algorithms that do not include previously required tests (e.g., Western blot). New to the case definition is the inclusion of criteria for differentiating HIV-1 and HIV-2 infections and for recognizing early HIV infection (stage 0), during which viral loads might be high enough and CD4 T-lymphocyte counts low enough to be confused with stage 3 (AIDS). In addition, the revised definition consolidates the staging systems for adults/adolescents and children, simplifies surveillance criteria for opportunistic illnesses indicative of stage 3, and incorporates revisions of clinical criteria (i.e., medical record documentation) for reporting diagnoses without laboratory evidence. Because retroactive implementation of some features (e.g., the new staging system) of the 2014 case definition would be impractical, for this report, cases diagnosed before 2014 were classified according to the 2008 HIV case definition and cases diagnosed in 2014 were classified according to the 2014 HIV case definition.
A total of 35,606 cases of HIV infection were diagnosed in the United States during 2014 and reported to CDC as of December 2014. Blacks had the highest rate of diagnoses of HIV infection of all racial/ethnic groups (40.1 per 100,000 population) and accounted for 44.5% of diagnoses in 2014. Although HIV affects persons in all age groups, cases were most frequently diagnosed in adults aged 25–39 years. Areas with the highest rates (≥15.0) of diagnoses during 2014 were the District of Columbia, Florida, Louisiana, Mississippi, New York, South Carolina, and the U.S. Virgin Islands.
  1. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recomm Rep 2008;57(No. RR-10 ). PubMed
  2. CDC. Revised surveillance case definition for HIV infection—United States, 2014. MMWR Recomm Rep 2014;63(No. RR-3 ). PubMed

Influenza-Associated Pediatric Mortality

In 2004, the Council of State and Territorial Epidemiologists added influenza-associated pediatric mortality to the list of conditions reportable to the National Notifiable Diseases Surveillance System (1). A pediatric influenza-associated death is defined for surveillance purposes as a death resulting from a clinically compatible illness that was confirmed to be influenza by an appropriate laboratory or rapid diagnostic test in a person aged <18 years. From December 29, 2013 to January 3, 2015*, a total of 141 influenza-associated pediatric deaths were reported to CDC from 34 states and New York City.
Of the 141 influenza-associated pediatric deaths reported to CDC during 2014, four deaths occurred during the 2008–09 influenza season, six deaths during the 2009–10 influenza season, two deaths during the 2011–12 influenza season, 103 during the 2013–14 influenza season, and 26 during the 2014–15 influenza season. An influenza season spans the time period between MMWRweek 40 of a calendar year to MMWR week 39 of the following year. A total of 117 (83%) cases were associated with influenza A viruses, 20 (14%) with influenza B viruses, three (2.1%) with an influenza virus for which the type was not determined, and one (0.7%) death was associated with influenza A virus and influenza B virus co-infection. Of 117 influenza A viruses, subtype was determined for 70 (60%); 52 were influenza A (H1N1)pdm09 viruses and 18 were influenza A (H3N2) viruses.
Among the 141 deaths reported in 2014, a total of 18 (13%) occurred among children aged <6 months, 46 (33%) among those aged 6–59 months, 43 (31%) among those aged 5–11 years, and 34 (24%) among those aged 12–17 years; the median age at the time of death was 6.1 years (range: 3 days–17 years). The median age in 2014 is similar to previous influenza seasons during nonpandemic periods, but is lower than the median age of deaths observed during the 2009 pandemic.
Information on the location of death was available for 131 (93%) of the 141 children: 81 (62%) children died after being admitted to the hospital (73 were admitted to the intensive care unit), 30 (23%) died in the emergency department, and 20 (15%) died outside the hospital. Information on pre-existing medical conditions was reported for 136 (96%) children: 73 (54%) children had one or more underlying medical condition known to confer increased risk for complications from influenza (2). The most common group of underlying conditions was neurologic disorders (e.g., moderate to severe developmental delay, seizure disorders, cerebral palsy, mitochondrial disorders, neuromuscular disorders, and neurologic conditions), which was reported for 48 (35.3%) of 136 children. Eleven (8.1%) of 136 children had cardiac disease or congenital heart disease, 19 (14%) had chromosomal abnormalities and/or genetic syndromes, and 33 (24%) had a chronic pulmonary condition (e.g., asthma, cystic fibrosis, or other chronic pulmonary disease).
Among the 141 deaths in children, 69 children had specimens collected for bacterial culture from normally sterile sites. Of these, 24 (35%) had positive cultures, and two (8.3%) of the 24 were positive for more than one pathogen. Staphylococcus aureus was detected in five (21%) of 24 positive cultures; three were methicillin-resistant, and for two specimens methicillin-sensitivity testing was not done. Three cultures (13%) were positive for Streptococcus pneumoniae, six (25%) were positive for Group A Streptococcus, three (13%) were positive for Pseudomonas aeruginosa, and two (8.3%) were positive for Escherichia coli. Other bacterial pathogens identified included one each with Haemophilus influenzaeKlebsiella pneumoniae, and Streptococcusspecies.
Of 93 children aged ≥6 months at the time of illness onset for whom seasonal vaccination status was known, 20 (22%) had been vaccinated against influenza as recommended by the Advisory Committee on Immunization Practices (2,3). Twenty-three children were aged <6 months at the time of illness onset and ineligible for vaccination.
The number of influenza-associated pediatric deaths reported during 2014 was higher than that in nine of the previous 10 seasons, excluding the 2009 influenza A (H1N1)pdm09 pandemic. Influenza seasons typically span portions of two calendar years and can vary widely in terms of severity and timing of peak activity, thus affecting the number of deaths reported in a calendar year. The 2014–15 influenza season was moderately severe and peaked in late December 2014 (4). Continued surveillance for influenza-associated mortality is important to monitor the effects of seasonal and novel influenza, factors contributing to severe influenza-associated disease, and the influence of interventions among children.
  1. Council of State and Territorial Epidemiologists. Influenza-associated pediatric mortality. Position statement 04-ID-04.
  2. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2014–2015. MMWR Morb Mortal Wkly Rep 2014;63:691–7. PubMed
  3. Advisory Committee on Immunization Practices. Prevention and control of influenza with vaccines: interim recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR Morb Mortal Wkly Rep 2013;62:356. PubMed
  4. Appiah GD, Blanton L, D’Mello T, et al. Influenza activity - United States, 2014-15 season and composition of the 2015–16 influenza vaccine. MMWR Morb Mortal Wkly Rep 2015;64:583–90. PubMed
* For 2014, only influenza-associated pediatric deaths that were reported during MMWR week 1 through MMWR week 53 (December 29, 2013–January 3, 2015) are included in this summary.


Leptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Infection in humans occurs through direct or indirect contact with the urine of infected host animals including rodents (1,2), livestock (3), dogs (4), and many wildlife species. Initial signs and symptoms might mimic certain other febrile illnesses, making recognition difficult (5). Some cases of leptospirosis progress to severe, potentially fatal, disease with signs of multiorgan involvement that can include aseptic meningitis, jaundice, renal failure, pulmonary involvement, and hemorrhage (1,2).
Exposure risks for leptospirosis include recreational water activities (2,6), such as wading, swimming, rafting and kayaking, especially after heavy rainfall; contact with floodwaters; occupational exposures related to farming (6) and contact with host animals, such as occurs with slaughterhouse workers and veterinarians (2,7); and living in areas with rodent infestation (8). Cases of leptospirosis in the United States also have been linked to adventure racing and multisport events (9,10) and with travel to countries where leptospirosis is endemic.
The emergence of new risk groups; the lack of dynamic data on incidence, distribution, and risk factors; and the likely underestimation of disease incidence led to the reinstatement of leptospirosis to the list of nationally notifiable diseases by the Council of State and Territorial Epidemiologists in 2013. CDC officially began receiving case notifications through the National Notifiable Diseases Surveillance System (NNDSS) in January 2014. Leptospirosis is reportable in 46 jurisdictions, states, and territories.
In 2014, a total of 107 cases of leptospirosis were reported to NNDSS from 11 states and one territory. Sixty-nine (64%) cases were from Puerto Rico and 23 (21%) were from Hawaii. In the 50 states and the District of Columbia, of 38 total cases, 30 (79%) were male, a trend identified in previous reports (6). Of 35 cases with reported age, 31 (89%) were aged 15–64 years. After 19 years without standardized reporting of leptospirosis cases, increasing the awareness of leptospirosis among health care providers and improving the detection and reporting of leptospirosis cases is essential for improving understanding of the disease’s epidemiology in the United States.
  1. Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003;3:757–71. CrossRef PubMed
  2. Levett PN. Leptospirosis. Clin Microbiol Rev 2001;14:296–326. CrossRef PubMed
  3. Talpada MD, Garvey N, Sprowls R, Eugster AK, Vinetz JM. Prevalence of leptospiral infection in Texas cattle: implications for transmission to humans. Vector Borne Zoonotic Dis 2003;3:141–7.CrossRef PubMed
  4. Ward MP, Glickman LT, Guptill LE. Prevalence of and risk factors for leptospirosis among dogs in the United States and Canada: 677 cases (1970–1998). J Am Vet Med Assoc 2002;220:53–8.CrossRef PubMed
  5. Lo Y-C, Kintziger KW, Carson HJ, et al. Severe leptospirosis similar to pandemic (H1N1) 2009, Florida and Missouri, USA. Emerg Infect Dis 2011;17:1145–6. CrossRef PubMed
  6. Katz AR, Buchholz AE, Hinson K, Park SY, Effler PV. Leptospirosis in Hawaii, USA, 1999–2008. Emerg Infect Dis 2011;17:221–6. CrossRef PubMed
  7. Guerra MA. Leptospirosis. J Am Vet Med Assoc 2009;234:472–8,30.
  8. Vinetz JM, Glass GE, Flexner CE, Mueller P, Kaslow DC. Sporadic urban leptospirosis. Ann Intern Med 1996;125:794–8. CrossRef PubMed
  9. Stern EJ, Galloway R, Shadomy SV, et al. Outbreak of leptospirosis among Adventure Race participants in Florida, 2005. Clin Infect Dis 2010;50:843–9. CrossRef PubMed
  10. Sejvar J, Bancroft E, Winthrop K, et al. Leptospirosis in “Eco-Challenge” athletes, Malaysian Borneo, 2000. Emerg Infect Dis 2003;9:702–7. CrossRef PubMed


Listeria monocytogenes infection (listeriosis) is rare but can cause severe invasive disease (e.g., bacteremia and meningitis). Listeriosis is predominately acquired through contaminated food and occurs most frequently among older adults, persons with certain immunocompromising conditions, and pregnant women and their newborns. Pregnancy-associated listeriosis is usually a relatively mild illness for women, but can result in fetal loss or severe neonatal disease.
Listeriosis has been nationally notifiable since 2000. In 2014, the incidence of listeriosis reported to the National Notifiable Diseases Surveillance System (NNDSS) was 0.24 infections per 100,000 population. Progress toward the 2020 national target of 0.2 infections (1) is measured through the Foodborne Diseases Active Surveillance Network (FoodNet), which conducts active, population-based surveillance for listeriosis in 10 U.S. states. FoodNet reported a preliminary annual incidence of Listeria monocytogenes in 2014 of 0.24 infections, the same rate reported to NNDSS (2).
The Listeria Initiative is an enhanced surveillance system designed to aid in the rapid investigation of listeriosis outbreaks by combining molecular subtyping results with epidemiologic data collected by state and local health departments (3). As part of the Listeria Initiative, CDC recommends that all clinical isolates of L. monocytogenes be forwarded routinely to a public health laboratory for pulsed-field gel electrophoresis (PFGE) subtyping and that these PFGE subtyping results be submitted to PulseNet, the National Molecular Subtyping Network for Foodborne Disease Surveillance (4); clinical isolates also should be promptly sent to CDC for further characterization. In addition, communicable disease programs are asked to interview all patients with listeriosis promptly using the standard Listeria Initiative questionnaire, which is available in English and Spanish (
Beginning in September 2013, whole genome sequencing has been performed on all clinical isolates as part of a project conducted by CDC, state and local health departments, the Food and Drug Administration, the U.S. Department of Agriculture’s Food Safety and Inspection Service, the National Institutes of Health, and international partners (5). All isolate sequences are deposited in publicly available databases at the National Center for Biotechnology Information of the National Institutes of Health. The Listeria Initiative has aided in the timely identification and removal of contaminated food during several listeriosis investigations, including a multistate outbreak of 35 illnesses that was linked to commercially produced, prepackaged caramel apples in 2014 (6).
  1. US Department of Health and Human Services. Healthy People 2020 objectives.
  2. Crim SM, Griffin PM, Tauxe R, et al. Preliminary incidence and trends of infection with pathogens transmitted commonly through food—Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2006–2014. MMWR Morb Mortal Wkly Rep 2015;64:495–9. PubMed
  3. CDC. National Enteric Disease Surveillance: The Listeria Initiative. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2014.
  4. CDC. PulseNet.
  5. CDC. AMD projects: Learning from Listeria .
  6. CDC. Multistate outbreak of listeriosis linked commercially produced, prepackaged caramel apples made from Bidart Bros. apples (final update).

Lyme Disease

In 2014, the number of confirmed Lyme disease cases reported to CDC decreased compared with the number reported in 2013, but was higher compared to the number reported during 2010–2012. On the basis of reports to the National Notifiable Diseases Surveillance System (NNDSS), the geographic distribution of high incidence areas has expanded over time (1), with 381 counties reporting an incidence of ≥10 confirmed cases per 100,000 persons in 2014, compared with 324 counties in 2008. In addition, during 2013–2014, CDC and state and county health departments investigated several sudden cardiac deaths associated with Lyme carditis through case series, death certificate analysis, and review of NNDSS surveillance data (2,3). This rare but very serious complication of Lyme disease underscores the importance of reducing exposure to ticks and tick habitat.
  1. Kugeler KJ, Farley GM, Forrester JD, Mead PS. Geographic distribution and expansion of human Lyme disease, United States. Emerg Infect Dis 2015;21:1455–7. CrossRef PubMed
  2. CDC. Three sudden cardiac deaths associated with Lyme carditis—United States, November 2012–July 2013. MMWR Morb Mortal Wkly Rep 2013;62:993–6. PubMed
  3. Forrester JD, Meiman J, Mullins J, et al. Notes from the field: update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death—United States. MMWR Morb Mortal Wkly Rep 2014;63:982–3. PubMed


Measles was declared eliminated from the United States in 2000. Since then, elimination has been maintained through high population immunity along with adequate disease surveillance and public health response capacity (1,2). Nonetheless, because measles remains endemic in much of the world, importations continue to result in sporadic cases and outbreaks in the United States, which can be costly to control (3). As in the other years since elimination, most measles cases (99%) were import-associated (4).
A measles outbreak is defined as a chain of transmission involving three or more cases. A total of 23 outbreaks occurred in 2014, accounting for 81% of the total cases. There were 63 international importations, the most since 2011, and 43% of importations originated from the Philippines. The largest outbreak accounted for 57% of the cases. In each of these outbreaks, transmission occurred after a U.S. resident traveler introduced measles into communities with pockets of persons unvaccinated because of philosophical or religious beliefs. This allowed for spread to occur, mainly in households and community gatherings, before public health interventions could be implemented (CDC, unpublished data, 2014).
The largest outbreak occurred in Ohio, which started when unvaccinated travelers visited the Philippines where a large outbreak of measles was occurring. The travelers returned to Ohio and spread the disease to other unvaccinated persons (89% unvaccinated, 10% unknown, and 1% with 1 dose). This outbreak was the largest outbreak in the United States since 1992.
  1. Hutchins SS, Bellini WJ, Coronado V, Jiles R, Wooten K, Deladisma A. Population immunity to measles in the United States, 1999. J Infect Dis 2004;189(Suppl 1 ):S91–7. CrossRefPubMed
  2. Papania MJ, Wallace GS, Rota PA, et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr 2014;168:148–55. CrossRef PubMed
  3. Parker AA, Staggs W, Dayan GH, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006;355:447–55.CrossRef PubMed
  4. Council of State and Territorial Epidemiologists. Revision of measles, rubella, and congenital syndrome case classification as part of elimination goals in the United States. Position statement 2006-ID-16.

Meningococcal Disease

Neisseria meningitidis is an important cause of bacterial meningitis and sepsis in the United States. In 2014, rates of meningococcal disease continued to be at historic lows in the United States (0.18 cases per 100,000 population). CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine use of quadrivalent (serogroup A, C, W, and Y) meningococcal conjugate vaccine in adolescents and others at increased risk for disease (13). In 2014, coverage with at least 1 dose of meningococcal conjugate vaccine was 79.3% among adolescents aged 13–17 years in the United States; however, by state, coverage ranged from 46.0%–95.2%, including the District of Columbia (4). Coverage with ≥2 doses of meningococcal conjugate vaccine among adolescents aged 17 years was 28.5% (4).
Two serogroup B meningococcal vaccines were licensed for use in the United States in 2014 and 2015. Both vaccines are approved for use in persons aged 10–25 years. In 2015, ACIP recommended routine use of serogroup B meningococcal vaccine in certain groups at increased risk for disease (5). A serogroup B meningococcal vaccine series also can be administered to adolescents and young adults aged 16–23 years to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for serogroup B meningococcal vaccination is 16–18 years (6).
  1. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No.RR-2 ). PubMed
  2. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184–91. CrossRef PubMed
  3. MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep 2014;63:527–30. PubMed
  4. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:784–92. CrossRef PubMed
  5. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal (MenB) vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep 2015;64:608–12. PubMed
  6. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal (MenB) vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep 2015;64:1171–6. CrossRef PubMed


In 2014, a total of 1,223 cases of mumps were reported in the United States with an overall incidence rate of 0.38 cases per 100,000 persons. Most (N = 883 [72%]) mumps cases reported in the United States during 2014 were from three states (Ohio, Illinois, and Wisconsin) and New York City, all of which experienced university-based outbreaks. University-based outbreaks are known to occur despite high 2-dose vaccine coverage (1). Reported median vaccine-effectiveness for mumps vaccine is 78% for 1-dose and 88% for 2-doses (2). Close and prolonged contact likely facilitates mumps transmission.
  1. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008;358:1580–9. CrossRef PubMed
  2. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No. RR-4 ). PubMed

Novel Influenza A Viruses

In 2007, the Council of State and Territorial Epidemiologists added human infection with a novel influenza A virus to the list of conditions reportable to the National Notifiable Diseases Surveillance System (1). Novel influenza A virus infections are human infections with influenza A viruses that are different from currently circulating human seasonal influenza viruses. These viruses include those that are subtyped as nonhuman in origin and those that cannot be subtyped with standard methods and reagents used for currently circulating influenza viruses.
Influenza viruses that normally circulate in swine are called swine influenza viruses when isolated from swine, but are called variant viruses when isolated from humans. During 2005–2014, all reported novel influenza A human infections in the United States involved variant viruses rather than avian-origin influenza viruses. Although most persons identified with variant influenza virus infection report contact with swine preceding their illness, suggesting swine-to-human spread, limited human-to-human transmission of these viruses has occurred (2). Because the implications of ongoing transmission of these viruses between humans are potentially severe, prompt and thorough investigation of human infections with novel influenza viruses is critical so that risk for infection can be more fully understood and appropriate public health measures can be taken (3).
In 2014, three human infections with novel influenza A viruses were reported from two states (Ohio [two] and Wisconsin [one]) (4,5). All three cases involved infection with an influenza A (H3N2) variant virus (H3N2v). The median age of patients was seven years (range: 2–10 years), and all three were female. Reported symptoms associated with infection were fever (100%), cough (100%), fatigue (100%), shortness of breath (67%), muscle aches (67%), vomiting or diarrhea (67%), and conjunctivitis (33%); all three cases reported influenza-like illness (e.g. fever (≥100°F [37.8°C] with cough and/or sore throat). None had an underlying medical condition known to confer increased risk for complications from influenza (6). All three patients sought health care for their illness and one was hospitalized; all three fully recovered. All three reported direct contact with (e.g., touching or handling) or proximity to (e.g., walking through an area or coming within 6 feet of) swine in the week preceding illness onset. No likely human-to-human transmission of novel influenza A viruses was identified.
Transmission of variant influenza A viruses to humans usually occurs among persons with direct, unprotected contact with swine or environments where swine are or have been present (e.g., agricultural fairs, farms, and petting zoos). CDC conducts surveillance for human infections with novel influenza A viruses in conjunction with state and local public health laboratories year-round and conducts extensive epidemiologic investigations on each case. Any specimen with results suggestive of the presence of a novel influenza A virus or that cannot be subtyped using standard methods and reagents at a public health laboratory is immediately submitted to CDC for further testing. Surveillance for human infections with novel influenza A viruses is essential, and early identification and investigation of human infections with novel influenza A viruses are critical so that risk for infection can be more fully understood and appropriate public health measures taken.
  1. Council of State and Territorial Epidemiologists. Public health reporting and national notification for novel influenza A virus infection. Position statement 13-ID-14.
  2. Jhung MA, Epperson S, Biggerstaff M, et al. Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis 2013;57:1703–12. CrossRef PubMed
  3. Richards S, Glazier M, Masterson K, et al. Update: Influenza A (H3N2)v transmission and guidelines—five states, 2011. MMWR Morb Mortal Wkly Rep 2012;60:1741–4. PubMed
  4. Blanton L, Brammer L, Smith S, et al. Update: influenza activity—United States and worldwide, May 18–September 20, 2014. MMWR Morb Mortal Wkly Rep 2014;63:861–4. PubMed
  5. Rolfes M, Blanton L, Brammer L, et al. Update: influenza activity—United States, September 28– December 6, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1189–94. PubMed
  6. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2014–2015. MMWR Morb Mortal Wkly Rep 2014;63:691–7. PubMed


Reported pertussis cases in the United States increased 15% from 2013 (incidence: 9.0 per 100,000 population) to 2014 (10.4). Despite the national increase in reporting, a majority of states reported fewer cases in 2014 than in 2013 (32). However, in 2014, California reported the largest number of cases observed (8,723) since its 2010 pertussis epidemic (7,195) (1). Six additional states reported a ≥50% increase in cases (Connecticut, Delaware, Idaho, Maine, Nebraska, and South Dakota). Although the age distribution of reported cases is similar to that reported for 2013, peak incidence has shifted from children aged 10 years in 2013 to those aged 15 years in 2014, likely the effect of waning immunity among aging cohorts of adolescents vaccinated exclusively with acellular pertussis vaccines (24). A total of 13 deaths occurred among all age groups; eight of the deaths occurred among infants aged <1 year, who account for most pertussis-related deaths reported in the United States. Maternal Tdap vaccination during the third trimester of pregnancy remains the primary recommendation for prevention of pertussis in infants (5).
  1. Winter K, Glaser C, Watt J, Harriman K. Pertussis epidemic—California, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1129–32. PubMed
  2. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012;308:2126–32. CrossRef PubMed
  3. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013;131:e1047–52. CrossRef PubMed
  4. Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics 2015;135:981–9. CrossRef PubMed
  5. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013;62:131–5. PubMed


Plague is a highly virulent fleaborne zoonosis caused by Yersinia pestis. A median of eight cases are reported each year in the United States (1). Most human plague infections result from an infectious flea bite; however, domestic animals can become infected and transmit plague to humans. Bubonic and septicemic plague are common clinical forms of plague and are not transmissible to others. In contrast, persons with pneumonic plague can transmit infection to others via infective respiratory droplets (2).
During 2014, an outbreak of pneumonic plague occurred in Colorado involving four patients. All four had exposure to a dog with confirmed pneumonic plague; however, person-to-person transmission between two of these patients could not be excluded (3). This is the first documented transmission from a domestic dog to humans in the United States. Furthermore, this event represents the largest outbreak and the first instance of possible human-to-human transmission in the United States since 1924 (1,2).
  1. Kugeler KJ, Staples JE, Hinckley AF, Gage KL, Mead PS. Epidemiology of human plague in the United States, 1900–2012. Emerg Infect Dis 2015;21:16–22. CrossRef PubMed
  2. Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40:1166–72. CrossRef PubMed
  3. Runfola JK, House J, Miller L, et al. Outbreak of human pneumonic plague with dog-to-human and possible human-to-human transmission—Colorado, June–July 2014. MMWR Morb Mortal Wkly Rep 2015;64:429–34. PubMed


Q fever is a zoonosis caused by the obligate intracellular bacterium Coxiella burnetii. The primary route of exposure is inhalation of aerosolized birth products from livestock (e.g., cows, goats, or sheep). In addition, other routes of exposure, such as ingestion, tick bite, and sexual transmission, are possible. In 2014, a cluster of five suspect Q fever cases in New York was associated with a history of travel to Germany for live cell therapy (injections of cells from the organs or fetuses of nonhuman animals) (1). A case from Canada was also associated with the New York cluster. Health care providers should be aware of medical tourism for this live cell therapy and the associated risks.
  1. Robyn MP, Newman AP, Amato M, et al. Q Fever outbreak among travelers to Germany linked to live cell therapy—United States and Canada, 2014. MMWR Morb Mortal Wkly Rep 2015;64:1071–3. CrossRef PubMed


During 2014, one case of human rabies was reported in the United States. The case was reported from Missouri. The patient presented with neck pain that radiated down the left arm that progressed to left arm numbness and tingling, bilateral upper body tremors, anxiousness, and hallucinations. Because of the unexplained rapidly progressive encephalitis and self-reported hydrophobia, rabies was suspected. CDC antemortem testing confirmed a rabies virus variant associated with the tri-colored bat Perimyotis subflavus. Following diagnosis, life support was withdrawn and the patient died.
During 2014, the number of animals submitted to state and local laboratories for rabies diagnosis (104,313) increased 7.8% compared with 2013. A total of 5,988 animals were confirmed positive. Increases in the number of animals reported rabid were observed for the following species: sheep/goats (10.0%), skunks (9.8%), cats (9.2%), and bats (9.0%). The number of reported rabid dogs (50.8%), foxes (10.6%), cattle (8.9%), raccoons (4.2%) and horses/mules (3.3%) also decreased compared with 2013.


In 2014, the incidence of salmonellosis in the United States was 16.3 laboratory-confirmed infections per 100,000 population, approximately one and a half times the 2020 national health objectives target of 11.4 (1). Data from the Foodborne Diseases Active Surveillance Network (FoodNet), which conducts active surveillance for salmonellosis in 10 U.S. states, are used to measure progress towards Healthy People 2020 objectives. In 2014, FoodNet reported a preliminary annual incidence of Salmonella of 15.5, slightly lower than the rate reported to the National Notifiable Diseases Surveillance System (2). During 2014, as in previous years of surveillance, children aged <5 years had the highest reported incidence rates of salmonellosis. Salmonellosis is reported most frequently in late summer and early fall; in 2014, this seasonality was evident, with most reports during July–October.
Accounting for underdiagnosis, Salmonella causes an estimated 1.2 million illnesses annually in the United States; of these, an estimated 1 million are transmitted by food consumed in the United States (3). Salmonella can contaminate a wide range of foods, and different serotypes tend to have different animal reservoirs and food sources, making control challenging. The largest multistate outbreak of Salmonella infections in 2014 (serotypes Infantis, Newport, and Hadar) was traced to live poultry in backyard flocks; other notable outbreaks in 2014 were linked to cucumbers (serotype Newport), bean sprouts (serotype Enteritidis), nut butter (serotype Braenderup), clinical and college and university teaching microbiology laboratories (serotype Typhimurium), organic sprouted chia powder (serotypes Newport, Hartford, and Oranienburg), frozen feeder rodents (serotype Typhimurium), pet bearded dragons (serotypes Cotham and Kisarawe), mechanically separated chicken (serotype Heidelberg), and raw cashew cheese (serotype Stanley) (4).
  1. US Department of Health and Human Services. Healthy People 2020 objectives.
  2. CDC. Foodborne Diseases Active Surveillance Network.
  3. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis 2011;17:7–15. CrossRef PubMed
  4. CDC. Reports of selected Salmonella  outbreak investigations, 2014.

Shiga Toxin-Producing Escherichia coli

In 2014, the incidence of laboratory-confirmed Shiga toxin-producing Escherichia coli (STEC) infections in the United States was 2.0 cases per 100,000 population. FoodNet, an active, population-based surveillance system for enteric diseases, reported STEC incidence of 2.4 in 2014 (1). As in all previous years of surveillance, the age group with the highest incidence of reported STEC infections was children aged 1–4 years (9.0). In 2014, multistate outbreaks of STEC infection linked to foods included raw clover sprouts (STEC O121) and ground beef (STEC O157:H7) (2).
Public health actions to monitor, prevent, and control STEC infections are based on serogroup characterization. Development of postdiarrheal hemolytic uremic syndrome (HUS), a severe complication of STEC infection, is most strongly associated with STEC O157. Non-O157 STEC, a diverse group that varies in virulence, comprises over 50 other serogroups. Increased use of assays for the detection of Shiga toxins in clinical laboratories in recent years has led to increased reporting of non-O157 STEC infection (3). STEC can produce Shiga toxins (Stx): Stx1, Stx2, or both. In general, strains that produce certain types of Stx2 are the most virulent (4). Accounting for underdiagnosis, an estimated 96,000 illnesses are caused by STEC O157 and 168,000 illnesses by non-O157 STEC each year (5,6).
Stool specimens from patients with community-acquired diarrhea submitted to clinical laboratories should be tested routinely both by culture for STEC O157 and by an assay that detects Shiga toxins (or the genes that encode them). Detection of Shiga toxin alone is inadequate for clinical management and public health investigation; characterizing STEC isolates by serogroup and by pulsed-field gel electrophoresis pattern is important to detect, investigate, and control outbreaks.
  1. Crim SM, Griffin PM, Tauxe R, et al. . Preliminary incidence and trends of infection with pathogens transmitted commonly through food - Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2006–2014. MMWR Morb Mortal Wkly Rep 2015;64:495–9. PubMed
  2. CDC. Reports of selected E. coli  outbreak investigations.
  3. Gould LH, Mody RK, Ong KL, et al. Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis 2013;10:453–60. CrossRef PubMed
  4. Mody RK, Griffin PM. Fecal shedding of Shiga toxin-producing Escherichia coli: what should be done to prevent secondary cases? Clin Infect Dis 2013;56:1141–4. CrossRef PubMed
  5. Heiman KE, Mody RK, Johnson SD, Griffin PM, Gould LH. Escherichia coli O157 Outbreaks in the United States, 2003–2012. Emerg Infect Dis 2015;21:1293–301. CrossRef PubMed
  6. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis 2011;17:7–15. CrossRef PubMed


In 2014, the incidence of reported shigellosis in the United States was 6.5 infections per 100,000 population. This is comparable to the incidence of laboratory-confirmed shigellosis reported by FoodNet, an active, population-based surveillance system for enteric diseases, in 2014 (5.8), and is in line with fairly stable incidence rates observed in FoodNet during the previous decade (1,2). In 2014, as in previous years, the highest number of reported cases of shigellosis occurred among children aged <10 years. S. sonnei infections account for approximately 75% of shigellosis in the United States (3). Shigellosis does not demonstrate marked seasonality, likely reflecting the importance of person-to-person transmission.
Accounting for underdiagnoses, Shigella causes an estimated 500,000 illnesses annually in the United States; of these, an estimated 130,000 are transmitted by food consumed in the United States (3). Shigella is often transmitted person-to-person, including through sexual contact between men who have sex with men (MSM), and can also be transmitted by contaminated food or by contaminated water used for drinking or recreational purposes (4). Some cases of shigellosis are acquired during international travel (5,6) and have caused multidrug-resistant outbreaks in the United States (7). Childcare-associated outbreaks are common and are often difficult to control (8).
MSM and persons infected with human immunodeficiency virus appear to be at the greatest risk for infection with Shigella with decreased susceptibility to azithromycin (9,10). In 2014, the majority of isolates known to be resistant to azithromycin harbored mphA or ermB, macrolide resistance genes that are typically plasmid-encoded. For adults with suspected shigellosis, clinicians should obtain sexual histories, collect stool specimens, test for antimicrobial susceptibility, and counsel patients about prevention.
  1. Crim SM, Griffin PM, Tauxe R, et al. Preliminary incidence and trends of infection with pathogens transmitted commonly through food—Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2006–2014. MMWR Morb Mortal Wkly Rep 2015;64:495–9. PubMed
  2. CDC. Foodborne Diseases Active Surveillance Network—FoodNet 2013 surveillance report.
  3. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis 2011;17:7–15. CrossRef PubMed
  4. Gupta A, Polyak CS, Bishop RD, Sobel J, Mintz ED. Laboratory-confirmed shigellosis in the United States, 1989–2002: epidemiologic trends and patterns. Clin Infect Dis 2004;38:1372–7.CrossRef PubMed
  5. Baker KS, Dallman TJ, Ashton PM, et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis 2015;15:913–21. CrossRef PubMed
  6. Gray MD, Lampel KA, Strockbine NA, Fernandez RE, Melton-Celsa AR, Maurelli AT. Clinical isolates of Shiga toxin 1a-producing Shigella flexneri with an epidemiological link to recent travel to Hispañiola. Emerg Infect Dis 2014;20:1669–77. CrossRef PubMed
  7. Bowen A, Hurd J, Hoover C, et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin—United States, May 2014–February 2015. MMWR Morb Mortal Wkly Rep 2015;64:318–20. PubMed
  8. Arvelo W, Hinkle CJ, Nguyen TA, et al. Transmission risk factors and treatment of pediatric shigellosis during a large daycare center-associated outbreak of multidrug resistant Shigella sonnei: implications for the management of shigellosis outbreaks among children. Pediatr Infect Dis J 2009;28:976–80. CrossRef PubMed
  9. Bowen A, Grass J, Bicknese A, et al. Elevted risk for antimicrobial drug-resistant Shigella infection among men who have sex with men, United States 2011–2015. Emerg Infect Dis 2016;9. E-pub ahead of print.
  10. Bowen A, Eikmeier D, Talley P, et al. Outbreaks of Shigella sonnei infection with decreased susceptibility to azithromycin among men who have sex with men—Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 2015;64:597–8. PubMed

Syphilis, Congenital

From 2008 to 2012, the rate of reported congenital syphilis decreased from 10.5 to 8.4 reported cases per 100,000 live births (1). However, in 2013, the rate of reported congenital syphilis increased to 9.1. In 2014*, the rate increased to 11.6, a 27.5% increase relative to 2013. Historically, increases in congenital syphilis parallel increases in primary and secondary (P&S) syphilis among women. During 2013–2014, the reported P&S syphilis rate among women increased 22.7%.
During 2013–2014, the congenital syphilis rate increased in every region of the United States, but as in previous years, the highest rates in 2014 were reported from the South (15.5). Similarly, during 2013–2014, the congenital syphilis rate increased among most race/ethnicity groups including whites, blacks, Hispanics, and Asians/Pacific Islanders, but race and ethnic disparities persisted in 2014. The rate of congenital syphilis among non-Hispanic blacks (38.2) was 10.3 times the rate among non-Hispanic whites (3.7), and the rate among Hispanics (12.1) was 3.3 times the rate among non-Hispanic whites.
  1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.
* Rates for 2013 and 2014 were calculated using the 2012 live birth estimates and differ from the 2013 and 2014 rates presented in the figures and table 7 (calculated using 2013 and 2014 live birth estimates, respectively).

Syphilis, Primary and Secondary

In 2000 and 2001, the national rate of reported primary and secondary (P&S) syphilis cases reached the lowest rate (2.1 cases per 100,000 population) since reporting began in 1941. However, since 2000–2001, the P&S syphilis rate has increased almost every year. In 2014*, the rate was 6.3 in the United States, the highest rate reported since 1994 (1). Since 2000, increases in the P&S syphilis rate have primarily been attributable to increased cases among men, specifically among gay, bisexual, and other men who have sex with men (collectively referred to as MSM). In 2014, men accounted for the majority (90.7%) of all cases of P&S syphilis. Among male cases with known sex of sex partner(s), 82.9% occurred among MSM. However, during 2013–2014, the P&S syphilis rate increased 22.7% among women (from 0.9 to 1.1) and 14.4% among men (from 10.2 to 11.7). Increases in the overall, male, and female P&S syphilis rates were observed in every region of the country.
  1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.
* Rates for 2014 were calculated using the 2013 population estimates and differ from 2014 rates presented in the figures and table 7 (calculated using 2014 population estimates).


In 2014, a total of 11 confirmed and two probable trichinellosis cases were reported. Of these, a known or suspected source of Trichinella infection was documented for nine (69%) and included bear (six), free-range pork (one), pork from an unspecified source (one), and hamburger (one). No likely source of infection could be identified for four cases.
An outbreak of two confirmed (one each from Texas and Utah) and two probable cases (one each from Colorado and Washington) was reported among a group of six persons who hunted and consumed meat from a black bear in Alaska. The meat was consumed “somewhat rare” after being cooked on skewers over an open fire. The Washington State Public Health Laboratory detected Trichinella larvae in a sample of leftover bear meat via microscopy. The best way to prevent Trichinella infection is to thoroughly cook all meats to the USDA-recommended temperatures (as verified with a food thermometer) before consumption (1).
  1. CDC. Trichinellosis. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. .


Tuberculosis (TB) is one of the world’s deadliest airborne diseases. It is the leading cause of death worldwide of persons living with human immunodeficiency virus (HIV), causing one fourth of all HIV-related deaths. In 2014, an estimated 9.6 million persons worldwide developed TB, and 1.5 million died from the disease (1). One third of the world’s population has latent TB infection (LTBI), which can later develop into active disease (2). Many persons arrive in the United States annually from countries with high burdens of TB, including immigrants, refugees, students, or travelers.
In the United States, new cases of TB disease have been reported annually since 1953 to the National Tuberculosis Surveillance System (NTSS) in CDC’s Division of Tuberculosis Elimination (DTBE) (3). CDC receives data from 60 reporting jurisdictions (all 50 U.S. states, the District of Columbia, New York City, and eight U.S.-affiliated islands) through a standardized data collection form, the Report of Verified Case of Tuberculosis (RVCT). In 2009, the RVCT was revised and NTSS transitioned into a web-based reporting system.
The number and rate of TB cases have declined each year since 1993, representing steady progress toward the goal of TB elimination in the United States (<1 case per 1,000,000 population). However, in 2014, the number (9,421) of new TB cases and rate of 3.0 per 100,000 population marked the smallest annual decline of incidence and TB case rate (-2.2%) in more than a decade (4).
Among all TB cases in the United States, racial/ethnic minorities, especially foreign-born persons, are disproportionately affected. In 2014, the proportion of persons with TB who were foreign-born increased to 66% (6,215 of 9,421) of total cases (4). Non-Hispanic Asians had the largest number of TB cases and the highest incidence rate in 2014. Compared with non-Hispanic whites, the TB rate among non-Hispanic Asians in 2014 was approximately 30 times higher (17.8 versus 0.6).*
TB drug resistance continues to be a major concern. During 1996–2014, the percentage of primary multidrug-resistant (MDR) TB cases, (i.e., patients with no previous history of TB disease and resistant to at least isoniazid [INH] and rifampin [RIF]) has fluctuated between 1.3 and 0.9%. The percentage of U.S.-born patients with primary MDR TB has remained below 1%. However, of the total number of reported primary MDR TB cases, the proportion occurring in foreign-born persons increased from 25% in 1993 to 85% in 2014. In addition, 15 extensively drug-resistant TB cases (i.e., patients with resistance to INH and RIF, plus resistance to any fluoroquinolone and at least one of three injectable second-line anti-TB drugs [i.e., amikacin, kanamycin, or capreomycin]) have been reported since 2009; of these, 11 were among foreign-born persons (4).
To achieve TB elimination, intensified efforts are needed to address the persistent disparities that exist between U.S.-born and foreign-born persons and between whites and minorities in the United States. Improved awareness, testing, and treatment of LTBI and TB disease in minorities and foreign-born populations are essential to these efforts. DTBE is developing an initiative to enhance testing, monitoring, and treatment of LTBI to prevent progression to TB disease and accelerate the decline of TB.
  1. World Health Organization. Global tuberculosis report 2015, 20th edition.
  2. World Health Organization. 10 facts about tuberculosis.
  3. CDC. Quality assurance for tuberculosis surveillance data: A guide and toolkit, Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
  4. CDC. Reported tuberculosis in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services, CDC, October 2015.
* Race/ethnicity is presented differently than in tables 5 and 6. Persons of Hispanic ethnicity might be of any race.

Typhoid Fever

Typhoid fever is rare in the United States. Since 2009, an annual average of <400 cases has been reported. In 2014, a total of 349 cases were reported. Approximately 75% of U.S. cases are associated with international travel (1), and the risk for infection is highest for travelers visiting friends and relatives in countries where typhoid fever is endemic. These persons might stay for extended periods and are less likely than other travelers to seek pretravel vaccination and to observe strict safe water and food practices, possibly because of misperception of disease risk (2). The risk is also higher for travelers who visit areas where the disease is highly endemic, such as the Indian subcontinent, even for a short time (3). In 2011, CDC removed pretravel typhoid vaccination recommendations for 26 low-risk destinations; pretravel vaccination guidelines are available at (4).
  1. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999–2006. JAMA 2009;302:859–65. CrossRef PubMed
  2. Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med 2005;142:67–72. CrossRef PubMed
  3. Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 2004;39:186–91. CrossRef PubMed
  4. Johnson KJ, Gallagher NM, Mintz ED, Newton AE, Brunette GW, Kozarsky PE. From the CDC: new country-specific recommendations for pre-travel typhoid vaccination. J Travel Med 2011;18:430–3. CrossRef PubMed


As the 2-dose varicella vaccination program continues to mature and with the discontinuation of active surveillance for varicella, national surveillance is increasingly important for monitoring impact of the program. More states are reporting varicella cases to CDC through the National Notifiable Diseases Surveillance System; reporting of varicella cases to CDC from states and the District of Columbia increased from 29 in 2006 (when the second dose of varicella vaccine was recommended for children [1]) to 40 as of 2014. Although the number of states reporting has increased, varicella incidence has declined 84.3% from an average of 25.4 per 100,000 population during 2005–2006 to 4.0 in 2014.
To monitor impact of the varicella vaccination program, data from key variables such as age, vaccination status, disease severity (e.g., number of lesions), outcome of the case (e.g., hospitalized), and whether the case is associated with an outbreak, are used. In 2014, a total of 10,089 (99%) of 10,172 cases reported to CDC from 40 states had data on at least one of the key variables important for monitoring the varicella vaccination program; completeness was 95% (9,622) for age, 60% (6,077) for vaccination status, 43% (4,344) for disease severity, 8% (802) for whether the case resulted in hospitalization, and 84% (8,493) for whether the case was associated with an outbreak. Of the cases with data reported for each of the key variables, 52% (4,975) was for persons aged 1–9 years, 22% (2,165) for those aged 10–19 years, and 18% (1,726) for those aged >20 years; 55% (3,330) was for persons who had received at least 1 dose of varicella vaccine. Of those with information on number of doses, 56% (1,330 of 2,358) had received 2 doses, 48% (2,081) had mild disease presentation (<50 lesions), 3% (25) resulted in hospitalization, and 11% (919) were associated with outbreaks. Laboratory testing for varicella was performed for 25% (1,159 of 4,696) of reported cases, of which 79% (912 of 1,159) were laboratory confirmed.
Much of the varicella data should be interpreted with caution because of the large proportion of missing data. States continue improving varicella surveillance practices (2) and are working to increase completeness of reporting for the variables important for monitoring the varicella vaccination program. As varicella incidence continues to decline, national surveillance data will provide the information needed to monitor progress and changing varicella epidemiology.
  1. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(No. RR-4 ). PubMed
  2. Lopez AS, Lichtenstein M, Schmid SD, Bialek S. Assessment of varicella surveillance and outbreak control practices—United States, 2012. MMWR Morb Mortal Wkly Rep 2014;63:785–8. PubMed


The incidence of vibriosis, defined as infection caused by a species from the family Vibrionaceae other than toxigenic Vibrio cholerae O1 or O139, has increased during 2007–2014 (1). In 2012, an outbreak of V. parahaemolyticus infections was associated with consumption of shellfish harvested from Oyster Bay Harbor, New York (2). Now endemic on the Atlantic Coast, this same strain continued to cause illness in 2013 and 2014 (3).
  1. Newton A, Kendall M, Vugia DJ, Henao OL, Mahon BE. Increasing rates of vibriosis in the United States, 1996–2010: review of surveillance data from 2 systems. Clin Infect Dis 2012;54(Suppl 5 ):S391–5. CrossRef PubMed
  2. Martinez-Urtaza J, Baker-Austin C, Jones JL, Newton AE, Gonzalez-Aviles GD, DePaola A. Spread of Pacific Northwest Vibrio parahaemolyticus strain. N Engl J Med 2013;369:1573–4.CrossRef PubMed
  3. Newton AE, Garrett N, Stroika SG, Halpin JL, Turnsek M, Mody RK. Increase in Vibrio parahaemolyticus infections associated with consumption of Atlantic Coast shellfish—2013. MMWR Morb Mortal Wkly Rep 2014;63:335–6. PubMed

Viral Hemorrhagic Fever

Viral Hemorrhagic Fever (VHF) is a group of acute febrile illnesses that are caused by approximately 30 viruses (1). Many are of substantial public health concern, particularly in Africa and South America, with the possibility of importation to the United States. Nationally notifiable VHFs are those with documented person to person transmission: Crimean-Congo hemorrhagic fever, Ebola virus disease (EVD), Lassa fever, Lujo, Marburg, and several New World Arenaviruses (Junin, Machupo, Guanarito, Sabia).
The 2014–16 West African EVD epidemic is the largest in history, with approximately 28,000 cases and 11,000 deaths (2). Such large numbers of cases presented new challenges in effectively diagnosing patients with EVD, caring for affected patients, and containing the epidemic. In 2014, a total of 10 persons with EVD received medical care in the United States. Six were medically evacuated to the United States after having EVD diagnosed in West Africa (36); four had the disease diagnosed in the United States. The four EVD cases diagnosed in the United States consisted of traveler from Liberia with two subsequent nosocomial infections (711) and a medical aid worker who returned from Guinea (12). These were the first EVD cases to receive care in the United States. Previously, a patient with Marburg virus disease was cared for in Colorado in 2007 (13).
In response to the concern about importation of EVD to the United States, national and state level surveillance systems were enhanced in 2014 (1418). In October 2014, all airline passengers who had traveled to Liberia, Sierra Leone, and Guinea within the previous 21 days were diverted to five airports for admittance to the United States using enhanced screening methods (19). At risk travelers and health care workers were required to complete a 21-day active monitoring period (17,18). In addition, CDC responded to inquiries from state and local health officials and health care providers and facilitated testing of persons under investigation (20,21).
One imported case of Lassa fever was reported in April 2014. This is only the seventh known imported case to the United States (22). Lassa fever is endemic in West Africa, with an estimated 100,000 to 300,000 cases and 5,000 deaths annually.
  1. Rollin PE, Nichol ST, Zaki S, Ksiazek TG. Arenaviruses and filoviruses. In: Murray PR, Baron EJ, Landry ML, Jorgensen JH, Pfaller MA, eds. Manual of clinical microbiology, 11th edition. Washington, DC: ASM Press; 2015:1669–86.
  2. World Health Organization. Ebola Situation Report, November 2015.
  3. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371:2402–9. CrossRef PubMed
  4. Stephens DS, Ribner BS, Gartland BD, et al. Ebola virus disease: Experience and decision making for the first patients outside of Africa. PLoS Med 2015;12:e1001857. CrossRef PubMed
  5. Sueblinvong V, Johnson DW, Weinstein GL, et al. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med 2015;43:2066–75. CrossRefPubMed
  6. Goodnough A. (2014, October 10). After years of empty beds, a medical team in Omaha puts its skills into practice. The New York Times, p. A14.
  7. Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States—Dallas County, Texas, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1087–8. PubMed
  8. McCarty CL, Basler C, Karwowski M, et al. . Response to importation of a case of Ebola virus disease—Ohio, October 2014. MMWR Morb Mortal Wkly Rep 2014;63:1089–91. PubMed
  9. Regan JJ, Jungerman R, Montiel SH, et al. Public health response to commercial airline travel of a person with Ebola virus infection—United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:63–6. PubMed
  10. Chung WM, Smith JC, Weil LM, et al. Active tracing and monitoring of contacts associated with the first cluster of Ebola in the United States. Ann Intern Med 2015;163:164–73. . CrossRefPubMed
  11. Liddell AM, Davey RT , Mehta AK, et al. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 2015;163:81–90. CrossRef PubMed
  12. Yacisin K, Balter S, Fine A, et al. . Ebola virus disease in a humanitarian aid worker—New York City, October 2014. MMWR Morb Mortal Wkly Rep 2015;64:321–3. PubMed
  13. CDC. Imported case of Marburg hemorrhagic fever—Colorado, 2008. MMWR Morb Mortal Wkly Rep 2009;58:1377–81. PubMed
  14. Koonin LM, Jamieson DJ, Jernigan JA, et al. Systems for rapidly detecting and treating persons with ebola virus disease—United States. MMWR Morb Mortal Wkly Rep 2015;64:222–5. PubMed
  15. Sunshine G, Pepin D, Cetron M, Penn M. State and territorial Ebola screening, monitoring, and movement policy statements—United States, August 31, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1145–6. CrossRef PubMed
  16. Benowitz I, Ackelsberg J, Balter SE, et al. . Surveillance and preparedness for Ebola virus disease—New York City, 2014. MMWR Morb Mortal Wkly Rep 2014;63:934–6. PubMed
  17. Parham M, Edison L, Soetebier K, et al. Ebola active monitoring system for travelers returning from West Africa—Georgia, 2014–2015. MMWR Morb Mortal Wkly Rep 2015;64:347–50. PubMed
  18. Stehling-Ariza T, Fisher E, Vagi S, et al. Monitoring of persons with risk for exposure to Ebola virus disease—United States, November 3, 2014–March 8, 2015. MMWR Morb Mortal Wkly Rep 2015;64:685–9. PubMed
  19. Brown CM, Aranas AE, Benenson GA, et al. Airport exit and entry screening for Ebola—August–November 10, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1163–7. PubMed
  20. Karwowski M, Meites E, Fullerton K, et al. Clinical inquiries regarding Ebola virus disease received by CDC—United States, July 9-November 15, 2014. MMWR Morb Mortal Wkly 2015;63:1175–9.
  21. Goodman AB, Meites E, Anstey EH, et al. Clinical inquiries received by CDC regarding suspected Ebola Virus Disease in children—United States, July 9, 2014–January 4, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1006–10. CrossRef PubMed
  22. Amorosa V, MacNeil A, McConnell R, et al. Imported Lassa fever, Pennsylvania, USA, 2010. Emerg Infect Dis 2010;16:1598–600. CrossRef PubMed

Part 1

Summary of Notifiable Diseases in the United States, 2014

Data not available.
Not reportable (i.e., report of disease is not required in that jurisdiction).
— No reported cases.
Notes: Rates <0.01 after rounding are listed as 0.
Data in the MMWR Summary of Notifiable Diseases — United States, 2014 might differ from data in other CDC surveillance reports because of differences in the timing of reports, the source of the data, the use of different case definitions, and print criteria.